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ABSTRACT

Harrell, Murphy, N., Ph.D., University of South Alabama, August 2022. How Valuable
are Clinical Neuropsychological Assessments? A Meta-Analysis of Neuropsychological
Tests with Comparison to Common Medical Tests and Treatments.
Chair of Committee: Benjamin D. Hill, Ph.D.

There has been a general decrease in neuropsychological assessments at a time when
medical diagnostic technology and treatments have expanded, leading to a faulty
assumption that medical tests and healthcare treatments provide more reliable or valid
data than psychological assessments. A landmark report from the American
Psychological Association’s (APA) Psychological Assessment Work Group (PAWG)
found that validity coefficients for many psychological tests were indistinguishable from
those of medical tests (Meyer et al., 2001). An updated systematic review of the
advancement in neuropsychological testing is essential to the continued advancement of
the value of neuropsychological assessment in healthcare. This meta-analysis sought to
(1) summarize effect sizes of neuroimaging to diagnose dementia, medications to treat
chronic diseases, and neuropsychological tests to diagnose dementia and TBI, (2)
determine the differences (if any) in effect sizes between medical domains, and (3)
determine the differences (if any) in effect sizes between medical domains and
neuropsychological tests. EBSCO networks were searched for original research
examining the efficacy of neuroimaging for Alzheimer’s Disease (AD),
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neuropsychological tests for AD and traumatic brain injury (TBI), and medication to treat
memory impairment and cardiovascular events between clinical and control samples.
Studies were coded using a complex multi-comparison, outcome, and subgroup
schema. Data were analyzed under random-effects modeling. Of 6,668 studies identified,
78 were retained for primary and ancillary meta-analyses (715 effect sizes extracted;
35,810 clinical and 42,964 control participants represented). Primary results indicated a
significant difference between domains, such that neuroimaging (g = -1.603) and
neuropsychological tests (g = -1.591) both yielded greater effect sizes than medication
studies (g = -0.009]. Secondary results indicated the AD neuropsychological test effect
size [g = -2.213) was significantly different than the TBI neuropsychological test efficacy
[g = -0.649; Q(1) = 42.821, p = 0.000]. Additionally, results indicated nonsignificant
effect sizes for both memory impairment medications (g = -.052) and aspirin for
cardiovascular events (g = .017). CONCLUSIONS: The diagnostic efficacy of
neuroimaging and neuropsychological tests were both substantial and non-significantly
different from one another. These findings provide clinicians and consumers with
convincing evidence that neuropsychological tests are a reliable diagnostic tool for
people with acquired and neurodegenerative brain disorders.

Keywords: neuropsychology, neuroimaging, medication, test efficacy
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CHAPTER I
INTRODUCTION

The 21st century has brought drastic changes to healthcare, and clinical
psychological assessment has not been immune to this medical evolution. Traditional
comprehensive psychological assessments that could take many hours to days, and once
defined psychological practice, fell victim to reimbursement constraints in the 1980s with
the expansion of managed care plans, leading many psychologists to abandon long and
high-cost evaluations (Piotrowski, 1999; Piotrowski, 2017). This decline in psychological
assessments when medical diagnostic technology was beginning a sudden advance,
particularly in imaging technology, led to a faulty assumption that medical tests provide
more reliable or valid data than psychological assessments. However, a landmark report
from the American Psychological Association’s (APA) Psychological Assessment Work
Group (PAWG) found that while psychological (including neuropsychological) and
medical tests have varying degrees of validity, validity coefficients for many
neuropsychological tests were indistinguishable from those of medical tests (Meyer et al.,
2001). This psychological assessment white paper was highly influential but is now 20
years old. This dissertation aimed to replicate and extend the findings of the PAWG with
an emphasis on findings published in the last five years.
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In an examination of 144 meta-analyses and authoritative papers, Meyer et al.
(2001) found evidence that disputed the common perception regarding popular
psychological and medical assessments. Specifically, tests of cognitive abilities and
personality traits all produced a range of validity coefficients that varied largely as a
function of the criterion under consideration. Additionally, many projective and objective
personality tests, as well as cognitive tests (e.g., Rorschach, MCMI, MMPI, and WAIS),
produced medium to large effect sizes that were similar to popular medical tests such as
Papanicolaou tests (“pap smears”), mammography, magnetic resonance imaging (MRI)
and electrocardiograms. Finally, the PAWG concluded that many gold standard
psychological tests work just as well as medical tests to detect the same outcome, such as
neuropsychological testing detecting dementia on par with MRI (Meyer et al., 2001).
Despite the validation of psychological assessment Meyer et al. (2001) provided
with the PAWG white paper, there were several noteworthy critiques of their
methodology and interpretation of findings. These critiques ranged from the exclusion of
significant medical tests that possibly negatively impacted inferences drawn about
laboratory tests, creation of their own effect sizes (Garb, Klein, & Grove, 2002), incorrect
use of base rates and selection ratios (Smith, 2002), and the lack of meta-analyses that
supported the validity of assessment practices in either a forensic or a general clinical
context (Hunsley, 2002). In response, Meyer et al. (2002) defended the application of a
single effect size metric to all studies (they only used correlation values) because the
same information could not be determined by odds ratio (OR) and relative risk reduction
(RRR) magnitudes (e.g., Rosenthal, 1991). They also noted that research has found
limited support for the use of RRRs and ORs within evidence-based medicine (e.g.,
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Sackett, Deeks, & Altman, 1996) because they do not provide the most patient-relevant
estimates of effect. Finally, Meyer et al. (2002) defended their use of validity coefficients
as a “central foundation” for the merits of a test. However, they noted that clinicians
should consider the validity of tests in terms of ongoing inference probabilities instead of
relying on fixed base rates. This seminal article and subsequent rebuttal provided the
framework for APA to establish assessment guidelines. However, an updated systematic
review of the advancement in neuropsychological testing is essential to the continued
advancement of the value of neuropsychological assessment in healthcare.
To provide an updated analysis of the efficacy of neuropsychological tests
compared to medical tests, the current study aimed to systematically review recent
neuropsychological testing as well as studies of medical tests and treatments. To improve
on Meyer et al. (2001), analyses expanded beyond correlations as the singular proxy of
test effect size by synthesizing recent studies on the topic of interest using meta-analysis.
In addition to updating the seminal Meyer et al. (2001) paper on broad psychological test
efficacy, specific neuropsychological tests were examined. In the following sections, a
brief description of neuropsychological and medical tests are presented, followed by
factors affecting common perceptions of medical and psychological science as well as
statistics used in efficacy research. Next, effect sizes of contemporary medical and
psychological tests across several diagnostic tests and categories are reviewed. Finally,
the goals/hypotheses for an updated systematic review comparing the effect sizes of
neuropsychological and medical tests are discussed.
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CHAPTER II
LITERATURE REVIEW

2.1 History of Tests Within Psychology and Medicine
Broadly, science is defined as the systematic study of the physical and natural
world through observation and experiment (Science & Technology, 2002). The branches
of science are commonly divided into major groups, including formal sciences, natural
sciences, and social sciences. The field of medicine is considered a natural science,
whereas psychology falls under social sciences. Despite categorical differences,
psychology and medicine are considered applied sciences, applying evidence-based
knowledge to practical applications, such as inventions for advancing knowledge of
disease and solving human behavior and experience problems (Roll-Hansen, 2009). Both
psychological and medical tests are the application of scientific knowledge to screen,
diagnose, and monitor health aspects.
2.1.1 Psychological Tests
A psychological test is a systematic method for observing a person's behavior or
performance in the context of a numerical scale or category system (Anastasi & Urbina,
1997). Additionally, tests are used to measure differences between people or differences
in the same person over time. Rudimentary psychological tests date back to 2200 B.C. as
part of the Chinese imperial system in which officials were examined for fitness for duty
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(Gregory, 2004). Psychological tests can be divided into several broad categories:
intelligence and achievement tests, neuropsychological tests, personality tests, aptitude
tests, and public employment safety tests (Gregory, 2004). For this study,
neuropsychological tests will be reviewed in more detail.
Neuropsychological testing is a relatively straightforward process in which a test
or scale is administered to obtain a specific score. A descriptive meaning can then be
applied to the score using normative data (Gregory, 2004). Despite the overwhelming
breadth of neuropsychological tests, core principles constitute sound tests, including
standardization, objectivity, test norms, reliability, and validity (Schultz & Schultz,
2010). These core principles are key to examining neuropsychological tests' efficacy and
will be discussed in more detail below. This brief history establishes the sound
foundation that neuropsychological testing has in the field of psychology. However, a
clinical question cannot be answered solely by a test score. Neuropsychological tests
must be interpreted within a more comprehensive assessment to understand psychological
health and disease more adequately
2.1.2 Psychological Assessment
A psychological assessment can include numerous tools, such as norm-referenced
neuropsychological tests, self, and other report measures, interview information, school
or medical records, and observational data that are integrated to answer clinical questions
(American Psychological Association, 2013). The term assessment was used for the first
time in 1943 by the U.S. Office of Strategic Services (Fernández-Ballesteros, 2002). This
new assessment program for military officers represented an improvement in previous
psychological testing. It described how the individual was able to act in various situations
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(Du Bois, 1970). Subsequently, assessment has been used to link all psychology fields,
becoming a generic term when decisions (e.g., classification, prediction, selection,
counseling, intervention, or evaluation) about individuals must be made (FernándezBallesteros, 2002).
Neuropsychological assessment is a specialized subfield of psychological
assessment that measures brain-behavior relationships. Some of the primary purposes of
contemporary assessments are to (a) describe current functioning, including cognitive
abilities, symptom severity, and capacity for independent living; (b) confirm or adjust the
clinical impressions formed by less structured interactions; (c) to identify therapeutic
needs, and create a therapeutic plan; (d) aid in the differential diagnosis of emotional,
behavioral, and cognitive disorders; (e) monitor treatment over time to evaluate the
success of interventions; (f) manage risk; and (g) provide skilled, assessment feedback as
a therapeutic intervention in itself (Meyer et al., 2001).
Given the intricacy of neuropsychological assessments, the validity of
individualized, contextually embedded inferences is incredibly complex. Each assessment
method identifies useful data not available from other sources, and an assessment battery
is likely to generate findings that, at least superficially, appear conflicting or
contradictory (Meyer et al., 2001). Additionally, many different conditions can lead to an
identical score on a particular test (Shea, 1985). Contextual factors (i.e., history, observed
behavior, motivational context, etc.) play a large role in determining the final scores
obtained on neuropsychological assessments. To integrate this information, psychologists
must consider questions, symptoms, dynamics, and behaviors from multiple perspectives.
Tests employed in other scientific disciplines (i.e., magnetic resonance imaging [MRI],
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blood panel, and electroencephalogram [EEG]) are less affected by these factors (Meyer
et al., 2001).
2.1.3 Medical Tests
A medical test is used to diagnose, screen for, or monitor the process and
susceptibility of diseases and determine a course of treatment (Balogh, Miller, & Ball,
2015). The oldest known medical tests date before 400 BC (Berger, 1999). Medical tests
are classified by specialty, including consulting room tests, cardiovascular, dermatology,
otolaryngology (ENT), gastrointestinal, hematology, laboratory, neurological, and
radiology. A diagnostic test is used to determine the presence of disease, usually due to
patient-reported symptoms (Balogh et al., 2015). Screening tests are used to detect or
predict the presence of disease in at-risk individuals due to population norms, family
history, or workforce exposure (Balogh et al., 2015). Medical tests are used to monitor
the progress of or response to medical treatment, including continuous monitoring of vital
signs or repeated medical tests (Balogh et al., 2015). The most common medical tests
include analysis of bodily fluids, including blood, urine, and cerebrospinal fluid;
neuroimaging, such as X-rays, computerized tomography (CT), MRI, and positron
emission tomography (PET); endoscopy; measurement of heart, brain, and lung function
through an electrocardiogram (ECG), EEG, and pulmonary function tests; biopsies; and
genetic testing (Merk Manuals, 2010).
Results of medical tests are often interpreted based on a reference range or a set of
values, including upper and lower limits of a lab test based on a reference or healthy
group (Jones & Barker, 2008). This range is usually defined as the set of values that 95
percent of the normal population falls within, determined by collecting data from vast
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numbers of laboratory tests. The values often depend on factors such as age, sex, and
specimen type (blood, urine, spinal fluid) and can also be influenced by situations such as
fasting and exercise (Jones & Barker, 2008). Most frequently, patients undergo diagnostic
medical tests due to chronic diseases, including skin disorders, osteoarthritis, joint
disorders, back problems, metabolic disorders, and upper respiratory disease (St Sauver et
al., 2013).
2.1.4 Medical Assessments
A comprehensive medical evaluation, or comprehensive physical exam, assesses
all aspects of a person's health for medical screening purposes (Raffle & Gray, 2019). A
comprehensive medical evaluation includes an updated medical history, including
previous illnesses, surgeries, hospitalizations, medications, allergies, and family medical
history; vital signs checks (i.e., blood pressure, heart rate, and respiratory rate); visual
exam of the patient's physical appearance, speech, and walking ability; physical exam of
eyes, ears, nose, throat, neurological functioning, abdominal palpation, and
dermatological exam of skin and nails; laboratory tests; and neuroimaging (Raffle &
Gray, 2019). The patient's medical history and sex, and age determine which tests are
included. In recent decades, the efficacy of comprehensive medical examinations has
come under debate. For example, a recent meta-analysis found that routine medical
examinations did not measurably reduce the risk of illness or death and, conversely,
could lead to excessive diagnosis and over-treatment (Krogsbøll et al., 2012).
Conversely, Verghese et al. (2015) found that inadequate physical examinations account
for oversights in care, such as increased missed or inaccurate diagnoses, unnecessary or
delayed treatment, unnecessary cost and exposure to radiation, and complications caused
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by treatment. These results indicated that while comprehensive medical screenings might
not be beneficial in preventing disease, comprehensive diagnostic exams are crucial to
accurate diagnosis and treatment.
Research has indicated that while both medical and neuropsychological tests are
tools that provide scores, neuropsychological functioning requires a more comprehensive
assessment of numerous contextual factors to adequately interpret test scores (Meyer et
al., 2001). Conversely, these factors rarely have such significant effects on medical tests.
As an example, a low full-scale I.Q. score on cognitive testing could indicate severe
depression, a traumatic brain injury, or a developmental disability (Meyer et al., 2001).
Additionally, as discussed above, comprehensive medical examinations are often used for
screening purposes, whereas comprehensive psychological assessments are required for
an accurate diagnosis.
The complexities of psychological assessments pose challenges for research on
and communication of psychological test efficacy. Conversely, the interpretation of
medical test results often indicates the presence or absence of disease with fewer
alternative contributing factors. Because of this, trust in medical science is often stronger
than in psychological science. Public trust in science is a critical component of how test
efficacy research is regarded. The following section reviews the factors that affect the
trust in medical and psychological science and tests.

2.2 Factors Affecting Public Attitudes Toward Science
It is recognized that there is a gap between scientific findings and people’s
acceptance of them. In an examination of the most salient factors in driving acceptance of

9

science (Funk, Rainie, & Page, 2015), higher education is correlated with greater
knowledge about science and scientific processes (Kennedy & Hefferon, 2019).
Furthermore, scientific knowledge has an independent effect in predicting varying
attitudes on several science-related topics, even after controlling for demographic and
political differences (Funk et al., 2015). Acceptance of scientific data is not based on
educational attainment alone but also on people’s political and religious beliefs and
demographic variables, such as age, race, and gender (Funk et al., 2015). Demographic
variables, statistical literacy, and beliefs about source credibility play important roles in
understanding medical and psychological science acceptance.
2.2.1 Positive Attitudes Toward Medical Science
Laypeople believe numerous medical screening tests and preventative treatments
to be strongly efficacious in preventing and treating disease. However, Meyer et al.
(2001) examined 89 meta-analyses between 1988 and 1989 on medical tests and
treatments, finding only low to medium effect sizes for many medical tests and
treatments. These included: daily aspirin to reduce the risk of dying from a heart attack
(r = .02); the impact of chemotherapy on breast cancer survival (r = .03); routine
ultrasound on successful pregnancy outcomes (r = .01); the value of antihistamines for
reducing sneezes and a runny nose (r = .11); mammogram screening and detection of
breast cancer (r = .27); the effect of sleeping pills for short-term treatment of insomnia
(r = .30); and the impact of Viagra on improved sexual functioning (r = .38) (Meyer et
al., 2001). Nevertheless, despite these generally small effect sizes, general trust in
medical tests and treatments remains high (Funk et al., 2019). Exploring public
understanding of medical research and managed healthcare has indicated that factors
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maintaining this excessive optimism in the efficacy of medical tests and treatments
include blind trust in physicians, demographic variables, and inaccurate understanding of
scientific methods and results.
Though there has been some decline in trust in healthcare across the United States
(Huang et al., 2018), people generally continue to have a high degree of trust in medicine.
A recent Pew Research Poll (Funk et al., 2019) found that 74% of Americans have a
mostly positive view of medical providers. Additionally, while Americans trust medical
researchers at high rates (i.e., 68% have positive views of medical researchers), only 32%
of individuals believe medical researchers provide fair and accurate information (Funk et
al., 2019). Interestingly, trust in healthcare appears to be mediated by demographic
variables. Older Caucasian participants are more likely than their younger, minority
counterparts of similar status to question medical advice (Meyer, Ward, & Jiwa, 2012;
Smith, 2011). Overall, those with higher socioeconomic status (SES) are more likely to
question medical advice than lower SES participants (Meyer et al., 2012). Finally,
participants who perceived themselves at risk of a poor or uncertain outcome were
unlikely to doubt medical advice, whereas primary care patients were more likely to
doubt medical advice (Meyer et al., 2012).
Not only is trust in healthcare a strong maintaining factor in the assumed efficacy
of medical tests and treatments, but research has also indicated that laypeople do not
accurately understand statistical methods and results used in medical research
(Gigerenzer et al., 2007). In a recent meta-analysis, participants rarely had accurate
expectations of benefits and harms, and for many interventions, regardless of whether it
was a treatment, test, or screen, they tended to overestimate its benefits and underestimate
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potential harm (Hoffman & Marr, 2015). In addition to patient illiteracy, statistical
illiteracy among physicians also contributes to physician overconfidence in medical
research and tests. Studies have demonstrated that a substantial number of physicians do
not correctly understand medical statistics (Gigerenzer et al., 2007; Wegwarth,
Gaissmaier, & Gigerenzer, 2011), do not understand the scientific evidence for benefits
and harms (Neuner-Jehle et al., 2011), and do not report them accurately to patients
(Wegwarth & Gigerenzer, 2013). Counterintuitively, Wegwarth, Wagner, & Gigerenzer
(2017) found that when physicians provided patients with inaccurate scientific
information regarding the risks and benefits of cancer screening tests, patients were
actually more likely to follow physician recommendations. This review illustrates the
strong contribution of positional power and expectation to receptiveness to accept
treatment advice, with valid information playing a lesser role in motivating treatment
compliance.
In addition to increased scientific literacy (knowledge), individuals may need to
shift their epistemic cognition (beliefs about the nature of knowledge) and epistemic trust
(beliefs about source credibility) to accept scientific perspectives (Sinatra & Hofer,
2016). These cognitive processes influence learning, making medical decisions, and
choosing which medical findings to trust (Sinatra & Hofer, 2016). Individuals move from
an absolutist cognitive stance (knowledge viewed as objective, certain, and true) toward a
multiplistic stance (knowledge viewed as subjective, based on interpretation and opinion)
(Kuhn, Cheney, & Weinstock, 2000). Ideally, an evaluativist view is achieved where
objectivity and subjectivity are integrated, knowledge is perceived as contingent and
contextual, and research claims are critically evaluated (Kuhn, Cheney, & Weinstock,
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2000). However, evaluativism may be relatively uncommon and correlated with
increased education (Kuhn et al., 2000). People express absolutist processes more
commonly, favoring certainty and misinterpreting the role of tentativeness in science
(Sinatra & Hofer, 2016). This belief about the absoluteness of science creates
considerable challenges in effectively communicating science to the public, especially for
the media.
Although a great deal of opinion formation occurs in the direct exchange between
health care professionals and patients, people also form their opinions and attitudes of
scientific findings through media content (Kimmerle et al., 2015; Sapp et al., 2013). This
becomes problematic when media sources do not accurately convey the tentativeness of
most medical research findings (Jenson, 2008), as the general public favors research
certainty (Bromme & Goldman, 2014; Chang, 2015). How the news communicates
scientific findings—whether framed positively or negatively and presenting reliability as
weak or strong—can influence perceptions of medical research findings (Kimmerle et al.,
2015). However, this may be challenging, as research suggests that not all medical
research includes limitations, especially when the studies were industry-supported (Ter
Riet et al., 2013).
Overall, this information is critical to understanding the key factors that affect
medical research credibility among the general public. Specifically, people tend to accept
medical research findings because they have high trust in physicians and medical
researchers, have poor health literacy to make evidence-based decisions that might differ
from the physician’s recommendation, and absorb media that promotes medical research
as true without critical analysis of source credibility. While the public and physicians are
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generally overconfident in the efficacy and validity of medical tests and treatments, there
is a significant distrust by the public of psychological research. The following section
considers how the factors contributing to overconfidence in medicine may also propel
distrust in psychological research.
2.2.2 Negative Attitudes Toward Psychological Science
Psychological science elicits less respect from the general public than many
“hard” sciences, like biology, chemistry, economics, medicine, and physics (Janda et al.,
1998). The reasons for this are manifold, ranging from poor mental health literacy,
external and internal distrust of psychological research and results, and the perpetuation
of mental health stigma by the media and policymakers (Lilienfeld, 2012).
Mental health literacy is defined as knowledge about mental health, including
recognizing, managing, and preventing mental health problems (Jorm, 2012). Research
on layperson mental health literacy consistently reveals a widespread lack of knowledge
of mental health disorders (Jorm, 2012), the role of psychologists versus psychiatrists
(Patel, Caddy, & Tracy, 2018), and the use of psychological treatment for areas outside of
mental health disorders (i.e., as reducing divorce rates, physical health problems, and
improving organizational productivity) (Penn et al., 2008). In addition, mental health
literacy varies across demographics such that older adults (Sørensen et al., 2015), men
(Gibbons, Thorsteinsson, & Loi, 2015), and those with lower education (Fisher &
Goldney, 2003) tend to have less knowledge about psychological disorders and are less
likely to engage mental health treatment (Reavley, McCann, & Jorm, 2012).
Inadequate mental health literacy vastly affects the trust in psychological research
and treatment. Laypeople generally distrust psychological science (Keil, Lockhart, &
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Schlegel, 2010; Lilienfeld, 2012). For instance, only 30% of respondents believed
psychology attempted to understand behavior through scientific research, and 41%
believed that psychology is less rigorous than medical research (Penn et al., 2008). The
public’s negative attitudes about psychological science and mental health treatment have
discouraged people from seeking mental health care and other recovery-oriented services
(Corrigan et al., 2005).
Not only is distrust in psychology a strong maintaining factor in the assumed
inefficacy of psychological tests and treatments, but research has also indicated that
laypeople do not accurately understand statistical methods and results used in
psychological research. For example, McPhetres & Pennycook (2020) showed
participants graphs depicting a range of effect sizes in different formats. Even the largest
effect examined (corresponding to a Cohen’s d = .90) was considered small to moderate
in size by laypeople, underscoring how the public does not have the requisite background
to truly understand the significant effects of tests and interventions. Furthermore,
psychological research often reports effect sizes ranging from .1 to .2 (Wilson &
Golonka, 2012), further discrediting psychological research efficacy among laypeople.
Not only are valid psychology statistics not well understood, but people tend to discount
behavioral science when specific conclusions are undesirable (Munroe & Munroe, 2015).
However, people are more likely to believe a neuroscience explanation of a psychological
phenomenon than a purely psychological explanation (Greene & Cahill, 2012), even
when the neuroscience explanation was irrelevant (Fernandez-Duque et al., 2015;
Hopkins, Weisberg, & Taykor, 2016).
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In fairness to the public, research on psychological methodology has found a
significant problem with replicating psychological findings within social psychology
(Stanley et al., 2018). Meta-analyses have indicated a skew in publication practices, such
that studies with null results are often rejected for publication (Bakker, van Dijk, &
Wicherts, 2012; Schimmack, 2012). This practice has been related to an increase in
authors using questionable researcher practices known as “p hacking” to convert null
findings to statistically significant findings (John et al., 2012; Mitchell, 2014), resulting
in low generalizability of research findings (Ferguson, 2015). In addition, some of these
practices are related to social psychologists having an advocacy narrative of findings they
want to present, which further erodes public confidence in psychological research and
hurts the view of psychology as an objective science. This further promotes distrust of the
scientific rigor of psychological research (Schimmack, 2020).
These replication problems have received significant press coverage in recent
years (e.g., Berezow, 2012; Ferguson, 2015; Gutting, 2012), perpetuating a public stigma
against the validity of psychology as a science. Psychological researchers have begun
tackling these issues with discussions about replication failures and self-criticisms of
questionable research practices (Ferguson, 2015). The discussions have increasingly
moved into public forums, such as blogs, Twitter, and Facebook discussion groups,
making criticisms more accessible to journalists and the general public (Brumfiel, 2009).
Some of this public discussion has arguably influenced policymakers’ decisions
regarding psychological science (Ferguson, 2015; Nyhan, 2014) and invited unfavorable
comparisons to the “hard” sciences (Chambers, 2014).
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Trust in medical research and treatment was high among laypeople, but trust in
psychological treatment and research was poor. This differs by demographics, health
literacy, research design interpretation, and treatment effects. Finally, the media plays an
influential role in perpetuating trust in medical science and distrust in psychological
science. Given the research on the poor statistical understanding of reporting methods for
testing and treatment efficacy and the use of these analyses in the current systematic
review, the following section briefly reviews the statistical methods for reporting
psychological and medical research findings.

2.3 Evaluating Efficacy of Tests
In reviewing the medical and psychological literature, terms that deal with
evaluating medical services, such as efficacy, effectiveness, and efficiency, are
common. Efficacy evaluates how well a test, medication, program, or procedure works in
an experimental or "ideal" setting, such as controlled clinical trials. Effectiveness assesses
how well a test, medication, program, or procedure works under usual circumstances
when applied to the general population. Finally, efficiency evaluates the costs and
benefits of medical intervention (Burches & Burches, 2020). For this review, the
scientific measurement of medical and neuropsychological test efficacy is explored.
2.3.1 Neuropsychological Efficacy Statistics
Psychometrics is the scientific study, including the development, interpretation,
and evaluation of psychological tests and measures used to assess behavior variability
and its relation to psychological phenomena. In evaluating the quality of
neuropsychological measures, researchers are primarily concerned with test reliability
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(i.e., consistency), validity (i.e., the accuracy of interpretations and use), and fairness
(i.e., the equivalence of usage across groups) (Committee on Psychological Testing,
2015).
Reliability is the degree to which test scores are stable and consistent (Committee
on Psychological Testing, 2015). Test scores are thought to be composed of true and error
elements. Therefore, a standard error of measurement within a confidence interval (e.g.,
95%) describes that a person's true score falls within a given range of test scores
(Geisinger et al., 2013). There are generally four classes of reliability, test-retest:
consistency of test scores over time; inter-rater: consistency of test scores across
independent judges; parallel or alternate forms: consistency of scores across different
forms of the test; and internal consistency: consistency of items intended to measure the
same thing within the test (Committee on Psychological Testing, 2015). Within internal
consistency, split-half reliability (two halves of a test are compared) is measured to
determine an index of reliability. A common measure of internal consistency in
neuropsychological research is Cronbach's α, which is the mean of all possible split-half
correlations for an item set (Committee on Psychological Testing, 2015). A more reliable
measure contributes relatively less error to statistical analyses (Suhr, 2003).
Many factors can affect the reliability of a test score. These include the time
between two testing administrations, changes in subjects over time, or test-based factors
(Committee on Psychological Testing, 2015). A test can yield reliable scores in one
context and not in another, and inferences made from different reliability estimates are
not interchangeable (Geisinger et al., 2013). A test's reliability is essentially an index of
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the proportion of error variance in a test, as more error variance results in decreased
reliability.
While the scores resulting from a test might have good reliability, this finding
does not necessarily mean that the test scores are valid. Validity is defined as the degree
to which a test measures what it is supposed to measure (Kelly, 1927). Validity does not
refer to the measure or the test items being valid. Instead, validity refers to interpreting
test scores grounded in psychological theory and empirical evidence and demonstrates a
relationship between the test and what it claims to measure (Furr & Bacharach, 2013).
The field of neuropsychology, and broadly psychology, is concerned with three primary
types of validity: construct validity: the degree to which an individual's test scores
correlate with the theoretical concept the test is designed to measure; content validity: the
degree to which the test content represents the targeted subject matter; and criterionrelated validity: the degree to which the test's score correlates with other measurable,
reliable, and relevant variables thought to measure the same construct (Sattler, 2014).
Within neuropsychological testing, other kinds of validity have also been
examined: diagnostic validity: the degree to which psychological tests support an
appropriate diagnosis; ecological validity: the degree to which test scores represent
normal levels of functioning; and cultural validity: the degree to which test content and
procedures accurately reflect the socio-cultural context of the subjects being tested
(Committee on Psychological Testing, 2015).
Psychological test efficacy research relies on test theories such as Classical Test
Theory (CTT) and Item-Response Theory (IRT) to answer null hypothesis significance
testing (NHST) through the interpretation of a p-value (Fisher, 1925). The p-value
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determines if there is a significant difference between groups. The smaller the p-value,
the stronger the evidence that the null hypothesis is rejected (McLeod, 2019). One of the
many problems with NHST is that it encourages dichotomous thinking: either an effect is
statistically significant or not (Kline, 2004). Using a p-value to merely determine if there
is a significant difference between groups or test items does not provide useful
information for clinical application. Effect sizes and confidence intervals (CI) provide
more information about those clinical differences (Walker, 2007).
An effect size can be defined as a quantitative description of the magnitude of an
effect (Kelley & Preacher, 2012). Effect sizes are particularly prominent in medical
research, where the size of the treatment effect is important. In psychological research,
effect sizes only more recently became required reporting standards (APA, 2010). There
are many kinds of effect sizes, though most can be combined into groups: those
measuring differences between groups and those that describe the strength of the
association. Most prominently, Pearson's correlation coefficient r, Cohen's d, and odds
ratios are used, though odds ratios are less common in psychological efficacy research.
The correlation coefficient r indicates the amount of variance explained by the model and
ranges from no relationship (r = 0) to a perfect relationship (1 or -1) (Walker, 2007). The
classic rule of thumb for interpreting effect sizes suggests that an r of |.1| represents a
'small' effect size, |.3| represents a 'medium' effect size, and |.5| represents a 'large' effect
size (Cohen, 1992). Another common measure of effect size is d, sometimes known as
Cohen's d, which compares two means divided by the average of their standard
deviations. Cohen suggested that d=0.2 be considered a 'small' effect size, 0.5 represents
a 'medium' effect size, and 0.8 a 'large' effect size (Cohen, 1992).

20

While effect sizes contain more information than P values, it is also an estimate
calculated from statistical inference (Lee, 2016). That is, an effect size estimated from a
large sample is likely to be more accurate than one estimated from a small sample (Lee,
2016). Confidence intervals can provide a range of plausible values for both the mean
and effect size estimate. For example, a 95% CI of the mean calculated from a sample
implies that if the samples originate from the same population with the same extraction
method, 95% of their CI ranges would include the population mean (Dekking et al.,
2005). For all hypothetically sampled data from the same population and using the same
sampling method, the population's effect would fall within 95% of the calculated 95%
CIs for the effect size of these data (Lee, 2016). If this 95% CI contains "0," it indicates
"statistical non-significance." Providing the effect size (point estimate) and CI (the
precision of effects) is essential to understanding the magnitude of intended treatment
effects (Lee, 2016).
In terms of diagnostic ability, tests are also examined for sensitivity and
specificity and, subsequently, their predictive value. The sensitivity of a test is defined as
the test's probability of correctly identifying all those who do indeed have that condition
from among people who are known to have a condition (i.e., true positives) and not
categorizing other people as not having the condition when in fact they do have it (i.e.,
avoiding false negatives) (Trevethan, 2017). A positive predictive value is the probability
that people with a positive screening test result have the condition of interest. Specificity
is the probability that a sign will be negative, given that the disorder is not present.
Conversely, specificity is defined as a screening test's probability of correctly
identifying all those who do not have that condition among people who are known not to
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have a condition (i.e., true negatives) and, at the same time, not categorizing some people
as having the condition when in fact they do not have it (i.e., avoiding false positives)
(Trevethan, 2017). A negative predictive value is the probability that people with a
negative screening test result do not have the condition of interest (Trevethan, 2017).
These metrics are often reported as percentages, although sometimes as decimal
fractions, preferably accompanying 95% confidence intervals.
While sensitivity and specificity are not impacted by the base rate of the disorder
in question, the base rate of the diagnosis in the population of interest should also be
considered in clinical decision-making (Meehl & Rosen, 1955). Sensitivity and
specificity are concerned with the predictive ability compared to a "gold standard"
diagnostic test or best available reference standard. Within neuropsychological and
medical assessment, there are few, if any, genuine "gold standard" tests (Brodsky &
Lichtenstein, 2020). However, the use of randomized control trials as the reference
standard of a test or medication efficacy (Meldrum, 2000) is much more prevalent in
medical research than in neuropsychological research (Clay, 2010).
2.3.2 Medical Efficacy Statistics
To understand disease etiology and provide effective treatment for persons with a
given disease, it is essential to accurately distinguish between patients who do not have
the disease of interest through screening and diagnostic tests (Krousel-Wood, Chambers,
& Muntner, 2006). However, it is important to assess the quality of these tests for
accurate interpretation and clinical decision-making by using what have been termed
medical and pharmaceutical statistics due to their heavy use in those areas (Dodge &
Commenges, 2006).
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Test validity (sensitivity and specificity as reviewed above) and predictive values
(PPV and NPV as reviewed above) are critical components of quality medical tests. The
tests that a provider chooses to diagnose or monitor a medical condition are based on
their ability to distinguish whether the condition is present or not (i.e., sensitivity and
specificity) (Krousel-Wood et al., 2006). A test's specificity is crucial when it is
necessary to confirm a diagnosis that requires potentially dangerous therapy. Likewise,
PPV and NPV are key in considering the probability of the disease given the patient's
population (Krousel-Wood et al., 2006). In populations with high disease prevalence,
there is greater confidence that a positive test result is a true positive and increased
suspicion that a negative test result is a false negative. The reverse is true in populations
where the prevalence of the disease is rare (Krousel-Wood et al., 2006). Therefore,
adequate test validity and predictive power are crucial for effective healthcare decisionmaking.
Medical research also reports effect sizes, especially within meta-analysis reports.
Much of the medical literature refers to effect size estimates such as relative risk (RR)
and odds ratios (OR). Both provide a measure of the strength of the relationship between
a factor and a disease or outcome. OR is the ratio of the odds of an event in one group
compared to the odds of the event in the other group (Ranganathan, Pramesh, & Buse,
2015). The RR is the ratio of risk in an exposed group versus the risk of the event in the
nonexposed group (Ranganathan et al., 2015). If the outcome is the same in both groups
(RR = 1), it is indicative of no difference in risk (or odds) between the intervention and
placebo or control group (Ranganathan et al., 2015). An RR (or OR) greater than 1.0
indicates an increase in risk (or odds) among the exposed compared to the unexposed
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group, whereas an RR (or OR) less than one indicates a decrease in risk (or odds) in the
exposed group (Ranganathan et al., 2015). Among 171 medical publications, reported
ORs ranged from 1.17 to 290.00 and had a median value of 2.16 (Chen, Cohen, & Chen,
2010).
The relationship between OR and RR is complex and often used interchangeably,
though incorrectly (Ranganathan et al., 2015). When there is an association between an
exposure and an outcome, an OR exaggerates the estimate of the relationship (is farther
from 1.0 than RR). Thus, when RR <1, OR is lower than RR. However, when RR is more
than 1.0 OR is higher than RR when the outcome is rare (typically <10%), the value of
OR is not too different from that of RR. The two can be used interchangeably,
irrespective of whether the risk is lower or higher in the exposed group compared to the
unexposed (Sedgwick, 2014). As event rates increase, the two ratios diverge and can no
longer be used interchangeably (Ranganathan et al., 2015). Stated differently, when there
is a low base rate of an event, OR and RR will be very similar, but as the base rate
increases, OR will exaggerate the likelihood of an event compared to RR. Both OR and
RR have confidence intervals (CI). If a 95% CI excludes the value one, the ratio is
significant at p<0.05 (Krousel-Wood et al., 2006). Also reported, especially in
randomized control trials, is the risk difference (RD), sometimes called absolute risk
reduction. It is the difference in risk (probability) of an event between two groups. The
RD provides a measure of the public health impact of the risk factor and focuses on the
number of cases that could potentially be prevented by eliminating the risk factor.
In review, both psychological and medical research use significance testing to
measure test efficacy. The use of effect sizes and confidence intervals are prevalent in
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both types of research, though the use of odds ratios is more prevalent in medical
research than r or d in psychological research. While there is some focus on sensitivity
and specificity and predictive value in psychological tests, this is limited compared to the
prevalence of these statistics in measuring medical test efficacy.
2.3.3 Approaches to Measuring Outcomes
In ideal cases, a test will be evaluated in a comprehensive clinical trial where
every relevant outcome is assessed in a representative group of patients (Matchar, 2012).
Unfortunately, such trials are not routinely performed in practice because they are often
deemed unattainable (Trikalinos, Siebert, & Lau, 2009). More often, however, systematic
reviews and meta-analyses are conducted. A systematic review is a protocol-driven
comprehensive review and synthesis of data focusing on a topic or related key questions
(Russel et al., 2009). A meta-analysis is a specialized statistical analysis used to combine
the data derived from systematic reviews.
Meta-analyses generate estimates of a (weighted) average effect size, the
dispersion of effect sizes, and the homogeneity (or heterogeneity) of the entire set of
observed effect sizes and subgroups and support the exploration of the potential
moderators (Suurmond, van Rhee, & Hak, 2017). Combined effect sizes from metaanalyses should only be used as an outcome of a group or subgroup homogeneity if the
observed effect sizes are only for the domain defined by this specific group of
populations (Suurmond et al., 2017). Because relevant heterogeneity is normally found in
the social sciences, the main result of most meta-analyses is an insight into the dispersion
of true effects (Suurmond et al., 2017). In those cases, meta-analysis functions as a tool
for generating hypotheses about potential moderators of the effect.
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2.3.4 Critique of Statistical Differences Across Disciplines
Though there are similarities in evaluating test efficacy between medical and
neuropsychological research, including hypothesis testing, with effect sizes and
confidence intervals, many differences contribute to the misinterpretation of research
findings. Specifically, differences in the use and interpretation of effect sizes across
medical and neuropsychological test research pose challenges for direct efficacy
comparisons.
Research indicates a continued lag in teaching and the use of effect sizes in
psychological courses (Funder & Ozer, 2019). Effect sizes such as r work ideally with
continuous data found in psychological science. Much of the medical and
epidemiological literature uses binomial data (Ferguson, 2009). Additionally, odds ratios
are more often used with epidemiological data. This poses a problem when comparing
effect sizes across the two disciplines. Ferguson (2009) found that effect sizes in medical
research, such as relative risk, do not translate well into effect sizes such as r, such that
translation often underestimates medical research effect sizes.
Additionally, conventional definitions of effect sizes are inadequate for
interpreting most psychological phenomena (Funder & Ozer, 2019). For example, a metaanalysis of social and personality psychology literature found that the average effectsize r was .19 and that an r between .11 and .29 fell at the 25th and 75th percentiles,
respectively (Gignac & Szodorai, 2016). The authors suggested recasting Cohen's
guidelines in this light, such that correlations of .10, .20, and .30 could be
considered small, typical, and relatively large, respectively (Gignac & Szodorai, 2016).
Additionally, in the medical literature, odds ratios have often been confused with relative
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risk. For example, a meta-analysis of articles in two medical journals found that 26% of
the articles that used an odds ratio interpreted it as a risk ratio (Holcomb et al., 2001).
A major limitation in neuropsychological test research is the absence of "gold
standard" tests (Tommasi, Ferrara, &, Saggino, 2018). In the absence of a perfect test,
multiple imperfect tests are used to gain an estimate, increasing the risk of incorrect
interpretation (Lesaffre, Speybroeck, & Berkvens, 2007). Before performing the test, it is
necessary to add prior information, such as knowledge about the parameter of interest
(e.g., the probability that a person is affected by a mental disorder). This previous
knowledge constitutes the prior probability of the parameter, allowing for Bayesian
analysis of the combination of this prior probability with the collected data to yield an
estimate (Lesaffre et al., 2007). However, research has found that most
neuropsychologists and other clinical diagnosticians either neglected or misused base rate
information when presented in a similar format to that they would be expected to
encounter the information (Labarge, McCaffrey, & Brown, 2003).
Additionally, despite neuroimaging being seen as an exact and highly sensitive,
and specific technology, research has found high false-positive rates in neuroimaging
literature due to low power caused by small sample sizes (Button et al., 2013; Yarkoni,
2009). Specifically, meta-analyses of fMRI research found that the most popular
statistical analysis methods generate up to 70% false-positive results in null data (Eklund,
Nichols, & Knutsson, 2016). Similar conclusions have been reached in analyses of
diffusion-weighted MRI reconstructions of white matter pathways that have been
reported to be dominated by false-positive outcomes (Maier-Hein et al., 2016).
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2.4 Review of Effect Sizes in Medical Research
Given the high level of trust the public places in physicians discussed previously,
people are apt to follow physician recommendations concerning diagnostic tests and
treatments. As discussed above, Meyer et al. (2001) demonstrated small effect sizes for
many medical tests that were considered highly effective 20 years ago. Research
documenting low efficacy across medications and diagnostic tests is discussed.
2.4.1 Known Medical Risk Factors
In examining the effects of alcohol on cancer, Jayasekara et al. (2016) found a
weak non-linear dose-response relationship for breast cancer and a positive linear doseresponse relationship for upper aero-digestive tract (UADT) cancer and colorectal cancer.
The pooled RRs were 1.28 (95% confidence interval, CI: 1.07-1.52) for breast, 2.83 (95%
CI: 1.73-4.62) for UADT, 4.84 (95% CI: 2.51-9.32) for oral cavity and pharynx, 2.25
(95% CI: 1.49-3.42) for larynx, 6.71 (95% CI: 4.21-10.70) for esophageal and 1.49 (95%
CI: 1.27-1.74) for colorectal cancer. It would appear that alcohol consumption has a huge
effect on oral and pharyngeal cancers and esophageal cancer, with much smaller effects
on other cancers. However, this information cannot be truly understood without
considering the base rate of these cancers. The base rate of breast cancer is 13% in
women, the base rate of UADT cancer is 8%, the base rate of colorectal cancer is 4%, the
base rate for oral and pharyngeal cancer is 0.6%, the base rate for laryngeal cancers is
0.3%, and the base rate for esophageal cancer is 0.8% for men and 0.2% in women.
Understanding this base rate information now lets the consumer understand that alcohol
increases the rate of breast cancer from 13% to 16.6% in women, increases the rate of
UADT cancer from 8% to 22.6%, increases the rate of colorectal cancer from 4% to 6%,
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increases the rate of oral and pharyngeal cancer from 0.6% to 2.9%, increases the base
rate for laryngeal cancers from 0.3% to 0.7%, and increases the base rate for esophageal
cancer from 0.8% to 5.4% for men and 0.2% to 1.34% in women. With this information,
it is clear that alcohol consumption poses a greater likelihood of causing breast or UADT
cancer for an individual than for any of the other cancers, which are all low likelihood
events, despite the RR associated with increased alcohol being much larger for the other
cancers. This illustrates that the actual utility of medical advice for the patient is strongly
connected to the base rate of an event and not just an increased OR or RR associated with
a variable.
In regard to salt intake, a meta-analysis of five studies found adverse effects of
salt intake on health outcomes, including mortality (HR per unit increase in
sodium/potassium ratio was 1.13, 95% CI: 1.01-1.27, p = .04) (Cook, Appel, & Whelton,
2016); cardiovascular disease (HR: 1.36, 95% CI: 1.09-1.70; p = 0.007) (Mills et al.,
2016); and kidney disease and initiation of dialysis (sub‐hazard ratio (sHR) 1.17; 95% CI:
1.02-1.33) (Smyth et al., 2016). These are generally modest increases in outcomes
associated with the level of salt consumption despite the widely held belief by individuals
that salt is highly deleterious to their health, particularly when the effect is considered in
actual terms of the number of new cases. Additionally, looking at cholesterol and the risk
of stroke, a meta-analysis by Peters et al. (2016) indicated that raised total cholesterol is a
risk factor for coronary heart disease (CHD) with pooled RR of 1.20 (95% CI: 1.16-1.24)
in women and 1.24 (95% CI: 1.20-1.28) in men, resulting in a RRR of 0.96 (95% CI:
0.93-0.99) for CHD associated with a 1-mmol/L increase in total cholesterol. Again,
these could be considered modest increases in risk for heart disease compared to how
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individuals commonly view the association between cholesterol and cardiovascular
health. Additionally, corresponding RRs for the risk of total stroke was not associated
with cholesterol (1.01 [95% CI: 0.98-1.05]in women and 1.03 [95% CI: 1.00-1.05] in
men), with a pooled RRR of 0.99 (95% CI: 0.93-1.04) indicating that cholesterol level
had essentially no relationship with the likelihood of stroke.
Further, a meta-analysis (Sharp et al., 2011) of six longitudinal studies showed
that hypertension was significantly associated with an increased risk of vascular dementia
(OR: 1.59, CI: 1.29–1.95, p<0.0001) and roughly increased the odds of having vascular
dementia by half. However, the yearly incidence of vascular dementia over 70 is
approximately 0.9%, meaning that hypertension increased the rate of vascular dementia
from 0.9% to 1.4% in those aged 70 and older. This would not result in a large increase in
the absolute number of cases, particularly as considered by the layman. A similar
association between hypertension and the risk of prevalent vascular dementia was found
in the five cross-sectional studies (OR: 4.84, CI: 3.52–6.67, p < 0.00001) (Sharp et al.,
2011). Additionally, Shah, Sutaria, & Vyas (2020) found that the pooled prevalence of
stroke in patients with hypertension was 8.0% (95% CI: 5.1%–10.9%). The pooled
unadjusted odds ratio of stroke in patients with hypertension compared to those without
was 1.46 (95% CI: 1.07–1.99, I2 55.6, n = 7 studies) (Shah et al., 2020), meaning the
effect of hypertension on stroke was a 2% increase in individuals having a stroke.
Additionally, research on the association between risk factors and post-stroke dementia
(PSD) indicated that six variables were PSD risk factors. The pooled relative ratio (RR)
of atrial fibrillation was 1.68, previous stroke 1.59, myocardial infarction 1.40,
hypertension 1.36, diabetes mellitus 1.25, and previous transient ischemic attack 1.25,
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respectively (Surawan et al., 2017). These were statistically significant predictors of
increased risk but were more modest effects than would likely be assumed by the general
public.
Finally, compared to patients without obstructive sleep apnea (OSA), patients
with OSA were significantly associated with cerebral small vessel disease MRI findings
of white matter hyperintensity (WMH) and asymptomatic lacunar infarction (ALI) with a
pooled OR of 2.31 (95% CI: 1.46-3.66) and 1.78 (95% CI: 1.06-3.01), respectively.
However, there was no significant relationship between OSA and cerebral microbleeds
(CMBs), with a pooled odds ratio (OR) of 2.15 (95% CI: 0.64-7.29)
(Chokesuwattanaskul et al., 2020). Clearly, there is a connection between OSA and small
vessel ischemic changes, but this may not be as large an absolute increase in white matter
change and vascular events as the general public and healthcare providers believed.
Overall, these results indicate that most effect sizes for these commonly known
associations between risk factors and health outcomes were less than the average reported
OR of 2.16 found in the general medical literature (Chen et al., 2010). While the effect
sizes for the associations such as the effects of alcohol consumption on the risk of cancer
or the relationship between hypertension and developing vascular dementia were robust,
the reviewed results suggest that effect sizes are generally small to medium-sized for
many known medical risk factors and not out of line with effects seen in the clinical
psychological literature.
2.4.2 Medication Efficacy
In a meta-analysis of community-based cohorts of people aged 55 years and older,
Ding et al. (2020) examined the association between antihypertensive medications
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(AHM) with incidents of dementia. There was evidence to show that those using any
AHM had a reduced risk of developing dementia (HR: 0.88, 95% CI 0.79–0.98) and
Alzheimer's disease (HR: 0.84, 0.73–0.97) (Ding et al., 2020). However, there was no
evidence to support that a specific AHM drug class was more effective than others in
lowering the risk of dementia, indicating that any AHM for hypertensive blood pressure
might reduce the risk for dementia (Ding et al., 2020). Hughes et al. (2020) found similar
results for the effect of AHM on reducing the risk of incidence of cognitive impairment
or dementia (OR: 0.93, 95% CI: 0.88-0.98, absolute risk reduction: 0.39%, 95% CI:
0.09%-0.68%, I2 = 0.0%); lowering blood pressure was not significantly associated with
a change in cognitive test scores.
There has been significant debate about the long-term use of aspirin to prevent
stroke and cardiovascular events. For example, Bartolucci, Tendera, & Howard, (2011)
conducted a meta-analysis of nine randomized control trials on aspirin's effects. The
meta-analysis suggested aspirin can significantly decrease total cardiovascular events
(OR: 0.865, 95% CI: 0.80–0.930; p<.001) and nonfatal myocardial infarction (MI) (OR:
0.813, CI: 0.667–0.992, p<0.042). Aspirin’s effects on decreasing stroke (OR: 0.919 95%
CI: 0.828–1.021, p<0.116), cardiovascular mortality (OR: 0.956, 95% CI: 0.799–
1.143, p<0.619), and all-cause mortality (OR: 0.945, 95% CI: 0.881–1.014, p<0.115)
were nonsignificant (Bartolucci et al., 2011). Further, in a meta-analysis of 14
randomized control trials, Lei et al. (2016) found that aspirin use was associated with a
modestly decreased risk of ischemic stroke than non-aspirin use (OR: 0.83, 95% CI:
0.74–0.93, p = 0.001). Specifically, the effect of aspirin on ischemic stroke in healthy
adults was significant but not especially large (OR: 0.83, 95% CI: 0.74–0.94, I2 =
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22%, p = 0.002). However, there was no difference in the risk of ischemic stroke between
aspirin and non-aspirin groups for patients with cardiovascular diseases (OR: 0.75, 95%
CI: 0.44–1.29, p = 0.30) (Lei et al., 2016). Additionally, it was determined that aspirin
potentially increased the risk of serious bleeding events in both healthy individuals and
patients with previous cardiovascular diseases, suggesting little protective benefit from
aspirin (Lei et al., 2016).
Buckley & Salpeter (2015) systematically reviewed the risks and benefits of
dementia medications. A review of 257 studies found that treatment with cholinesterase
inhibitors (ChEIs) showed no significant difference in progression to dementia nor in
global, cognitive, or neuropsychiatric outcomes for those with mild cognitive impairment
(MCI) (RR: 0.67; 95% CI: 0.55-0.83). Additionally, there were significantly more
adverse events in the ChEIs groups (RR: 1.09; 95% CI: 1.02-1.16), but no more serious
adverse events or deaths (Russ & Morling, 2012). ChEIs produced small statistically
significant improvements in cognitive, functional, and global outcomes for up to one year
for those with mild to moderate Alzheimer's (OR: 1.56, 95% CI: 1.32-1.85) and Lewy
body dementia (RR: 1.04; 95% CI: 0.43-1.65 to RR: 2.57; 95% CI: 0.90-4.23) (Birks,
2006; Wang et al., 2015). McShane et al. (2019) found differences in memantine efficacy
in mild AD compared to moderate-to-severe AD. Overall, there is a small clinical benefit
of memantine in moderate-to-severe AD, which occurs irrespective of whether they are
also taking a ChEI, but no benefit in people with mild AD, which is the patient group
where these medications are commonly prescribed despite problematic side effects.
Meta-analyses on effect sizes across various medication treatments indicate
significant results, though most are consistently small. There were robust findings for the
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efficacy of ChEIs in the treatment of MCI. While there are many well-established
medications for treating medical disorders, this brief literature review highlights the
importance of adequate effect size interpretation for adequate support of medication
intervention.
2.4.3 Neuroimaging Efficacy
For the purposes of this review, the efficacy of neuroimaging in screening,
diagnosis, and monitoring of disease trajectory will be reviewed. Identifying brain
biomarkers of disease risk is limited by measurement reliability. Measuring brain activity
using task functional MRI (fMRI) is a major focus of biomarker development; however,
task fMRI's reliability has not been systematically evaluated. Elliot et al. (2020) found
converging evidence demonstrating poor reliability of task-fMRI measures (mean
intraclass correlation coefficient (ICC) = .397). The test-retest reliabilities of activity in a
priori regions of interest across 11 common fMRI tasks were poor (ICCs = .067–.485)
(Elliot et al., 2020).
Schmand et al. (2014) found that neuropsychological assessment is more accurate
than MRI measures of brain atrophy for detecting disease progression in patients with
MCI or AD. Measurement at baseline and two-year follow-up of hippocampal atrophy,
cortical thickness, and performance on neuropsychological tests in memory clinic
patients were collected. The composite neuropsychological score decreased by 0.6 SD in
the impaired group and was unchanged in the normal group (Schmand et al., 2014).
Estimates of required sample sizes to detect a 50% reduction in the rate of change were
larger using the rate of hippocampal atrophy (n = 131) or cortical thickness (n = 488)
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compared to change scores on neuropsychological assessment (n = 62) (Schmand et al.,
2014).
In terms of the efficacy of imaging for detecting TBI severity, Amyot et al. (2015)
found that CT, MRI, and transcranial doppler ultrasound (TCD) were determined to be
the most useful modalities in the clinical setting. Specifically, in a review of publications
using CT scans, evidence suggests the efficacy of CT scans for detecting moderate to
severe TBIs, though less sensitive in detecting mild TBI. In mTBI, evidence suggests that
CT scanning is of limited usefulness in the clinical evaluation of patients presenting to
the ED, such that 24% of those who suffered a mild TBI displayed intracranial
abnormalities on a CT scan (Jacobs et al., 2010).
The sensitivity of MRI compared to CT scans has been well documented. Orrison
et al. (1994) documented that MRI's overall sensitivity for detecting abnormalities in
acute head trauma was 96.4%, and CT was 63.4%. Additionally, research has found that
an MRI improved a three-month outcome prediction better than a CT scan. Yuh et al.
(2013) found that one or more contusions on MRI are associated with poor 3-month
outcomes (OR: 4.5, p<.01) after adjusting for head CT findings and demographic,
clinical, and socioeconomic factors. Conversely, CT evidence of subarachnoid
hemorrhage was associated with a multivariate odds ratio of 3.5 (p < 0.01) for poorer 3month outcomes after adjusting for demographic, clinical, and socioeconomic factors
(Yuh et al., 2013).
TCD is an important tool for monitoring the course of TBI, evaluating the effect
of medical treatment or intervention, forecasting, and identifying high-risk patients after
TBI. Bouzat et al. (2016) found TCD thresholds had 80% sensitivity (95% CI: 56% -
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94%) and 79% specificity (95% CI: 74%-83%) to predict worsening neurologic
symptoms. The negative and positive predictive values of TCD were 98% (95% CI:96 to
100%) and 18% (95% CI: 11to 28%). In patients with mild TBI, the sensitivity and
specificity of TCD were 91% (95% CI: 59% - 100%) and 80% (95% CI: 75% - 85%),
respectively. The area under the ROC curve, including age and GCS, was significantly
improved with the adjunction of TCD. On admission, patients with abnormal TCD
showed a more altered disability rating on day 28 than those with normal TCD (Bouzat et
al., 2016). Overall, research on neuroimaging efficacy is significant for the use of MRI,
CT scans, and TCD to diagnose and monitor the course of AD and TBI.

2.5 Review of Effect Sizes of Neuropsychological Research
As discussed above, psychological research and treatment are often believed to be
ineffective. However, Meyer et al. (2001) established that effect sizes for
neuropsychological tests are at least as good as medical test effect sizes. Unfortunately,
there is a paucity of research documenting the effect sizes of neuropsychological
assessments as compared to more general psychological assessments. Therefore, the
following is a streamlined analysis of the diagnostic efficacy of neuropsychological
assessment.
2.5.1 Neuropsychological Test Efficacy
Neuropsychological assessment is the application of a variety of performancebased tests to assess functioning across multiple cognitive ability areas (Harvey, 2012).
These include memory, attention, processing speed, reasoning, judgment, problemsolving, spatial, and language functions. Performance on tests is compared to reference
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groups to determine whether performance is as or below expected (Harvey, 2012).
Neuropsychological assessment is commonly indicated for developmental neurocognitive
disorders (such as Attention-Deficit/Hyperactivity Disorder or ADHD), degenerative
illnesses (dementia), or head injury (TBI).
Screening tests for cognitive decline or impairment are frequently used as a standalone cognitive test or part of a larger cognitive assessment battery. The Mini-Mental
State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) are two
common screening measures for cognitive decline. Research has established both
screening tests as good predictors of post-stroke cognitive impairment. For example,
Salvadori et al. (2013) found that the MoCA baseline score is significantly associated
with post-stroke cognitive impairment (OR:1.4, 95 % CI: 1.1–1.8). Research has found
sensitivity and specificity for the MoCA to range from a sensitivity of 80.48% and
specificity of 81.19% (Ciesielska et al., 2016); 86% sensitivity and 75% specificity (Shen
et al., 2015); and 91.4 % sensitivity, 75.8 % specificity, 80 % positive predictive value,
and 89.3 % negative predictive value (Salvadori et al., 2013). For the MMSE, research
has found 66.34% sensitivity and 72.94% specificity (Ciesielska et al., 2016), 82%
sensitivity, and 78% specificity (Shen et al., 2016).
In an examination of neuropsychological tests from the Neuropsychological
Assessment Battery (NAB) to predict functional abilities (IADL) in dementia, Ashendorf
et al. (2018) demonstrated that ROC curves showed the strongest prediction of IADL
(AUC > 0.90) for memory measures (List Learning delayed recall, and Daily Living
Memory delayed recall) and Daily Living Driving Scenes. Furthermore, at a
predetermined level of specificity (95%), List Learning delayed recall (71%), and Daily
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Living Memory delayed recall (88%) were the most sensitive (Ashendorf et al., 2018). In
a longitudinal study of individuals over age 70 without dementia, Rabin et al. (2012)
found that episodic memory tests, such as the Free and Cued Selective Reminding Test
(FR-FCSRT) and immediate recall scores from the Logical Memory subtest of the
Wechsler Memory Scale-Revised) contributed to the prediction of AD (FR-FCSRT HR:
3.25, 95% CI: 2.24–4.69, p <.001, Logical Memory HR: 1.54, 95% CI: 1.04–
2.25, p<.03). Ewers et al. (2012) examined the accuracy of primary MRI and
cerebrospinal fluid (CSF) biomarker candidates and neuropsychological tests for
predicting the conversion from MCI to AD dementia. The best single predictors were
right entorhinal cortex (prediction accuracy = 68.5% [95% CI: 59.5, 77.4]) and TMT-B
test (prediction accuracy 64.6% [95% CI: 55.5, 73.4%]). In conclusion, short-term
conversion to AD is predicted by single biomarkers with equal accuracy as a
neuropsychological measure (Ewers et al., 2012).
Further, Summers & Sanders (2012) found that baseline neuropsychological test
performance predicted the outcome of mild cognitive impairment with 86.3% accuracy at
a 20-month follow-up. Specifically, impairments in visual episodic memory (PAL),
verbal episodic memory (RAVLT), visual, immediate memory span (SSP), working
memory (SWM), divided attention (CRT), and sustained attention and target detection
(RVP A) differentiated between participants who developed dementia, recovered from
MCI, or remained in stable MCI. Further, the measures accurately identified 100% of the
cases that progressed to AD. Sixty-five percent of the recovered cases were correctly
identified, with a further 10% classified as unimpaired controls. This resulted in the
correct classification of recovery from MCI in 75% of cases. Of those with stable MCI,
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88% were correctly classified using the same set of measures. The subset of measures
resulted in a false positive rate of 25% for classifying recovered cases as persistent MCI
and 4% of stable MCI as having progressed to AD. The measures had a false negative
rate of misclassification of stable MCI of 8%. This study highlights the predictive
reliability and validity of performance on multiple measures to diagnose AD instead of
relying on only poor episodic memory test performance (Summers & Sanders, 2012).
In examination of the criterion validity of the NAB in patients with TBI (Donders
& Levitt, 2012) found that patients with TBI were more than seven times more likely (n =
23, 43%) to have attention scores <80 than controls (n = 5, 9%), χ2 (n = 108) = 15.62, p <
.0001, OR: 7.27 (90% CI: 2.97–17.80). Similarly, these patients were more than eight
times more likely (n = 18, 33%) to have memory scores <80 than controls (n = 3, 6%), χ2
(n = 108) = 13.39, p < .0003, OR: 8.50 (90% CI: 2.87–25.19). Finally, patients with TBI
were also more than four times more likely (n = 8, 15%) to have Executive Functions
scores <80 than controls (n = 2, 4%), χ2 (n = 108) = 3.97, p < .05, OR: 4.52 (90% CI:
1.18–17.31) (Donders & Levitt, 2012).
Regarding effect sizes for neuropsychological tests to diagnose ADHD, Pauli-Pott
& Becker (2011) found that corresponding neuropsychological tasks predicted concurrent
and school-age ADHD symptoms. Mean effect sizes for response inhibition (r =.29),
vigilance/arousal (r = .27), and delay aversion (r =.38) were of medium to large
magnitude, the mean effect size for working memory was small (r = .18). Despite
widespread recognition that ADHD is a chronic neurodevelopmental disorder in at least
half of all cases, optimal diagnostic methods among adults remain elusive (Nikolas,
Marshall, & Hoelzle, 2019). In the examination of the utility of an extensive

39

neuropsychological battery for diagnosing ADHD among adults, Nikolas et al. (2019)
found that worse performance (indexed by higher scores) on CVLT short-delay free
recall (OR: 1.4, 95% CI: 1.03-1.9), Salthouse Listening Span trials (OR: 1.4, 95% CI:
1.1-1.9), DKEFS CWIT inhibition/switching (OR: 1.5, 95% CI: 1.1-1.9), TOVA RT
variability (OR: 1.4, 95% CI: 1.0-2.0), and TOVA omission errors (β = .43, p = .01, OR:
1.5, 95% [CI: 1.1-2.1]) all significantly and incrementally predicted membership in the
ADHD group compared with the non-ADHD group, with an overall classification
accuracy of 72.1% (Nikolas et al., 2019).
Generally, neuropsychological tests have been reported to have similar effect
sizes and accuracy rates as medical tests described in the previous section. However,
there is not a comprehensive synthesis of this literature. Therefore, for the current study,
recent studies examining the efficacy of MRI to diagnose dementia, neuropsychological
tests to diagnose dementia and TBI, and medication to treat memory impairment
(cholinesterase inhibitors and memantine) and cardiovascular events (aspirin) were
examined.

2.6 The Present Study
The overview of medical and psychological test effect size literature presented
above demonstrated the need for continued test efficacy research. Investigators have
examined the efficacy of medications, lifestyle choices, and neuroimaging for disease
prevention and detection. There is strong evidence that the public generally overestimates
the effectiveness of medical technologies and interventions. Additionally, there is
considerable research on psychological test efficacy for diagnosing and severity of
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neurocognitive disorders, daily functioning, psychopathology, and employee suitability.
Meyer et al. (2001) reported on psychological test validity compared to medical test
validity and found that psychological test validity was comparable to the validity of
medical tests. However, this research examined mostly meta-analyses from before 1999.
Additionally, the systematic review by Meyer et al. (2001) examined a broad range of
medical and psychological diagnostic tests with limited ability to draw direct
comparisons for similar diagnostic categories. Therefore, the current review drew from
recent studies within specific diagnostic domains.
Aside from the need for an update to the Meyer et al. (2001) white paper, a
greater issue motivated the conception of the present study. Research suggests a
significant discrepancy in the credibility of medical tests versus psychological tests
among consumers. Poling data suggests that consumers' trust in physicians and medical
research is greater than that of psychological research. Additionally, research on test
efficacy across the two disciplines utilizes different statistics and is reported differently
by the media, leading to consumer confusion. In consideration of effect sizes across
fields, the strength of association (r) or comparison of means (Cohen's d) is more
common than odds ratios (OR) or risk ratios (RR), which are prominent in medical test
efficacy (Ferguson, 2009). Further, effect sizes seen in the social sciences are often very
small (Rosnow 2003), and there is no agreement on what magnitude of the effect is
necessary to establish practical significance (Ferguson, 2009). This leads to difficulties in
their interpretation. Similar to effect sizes seen more commonly in psychological
research, interpretation of risk estimates in medical research is also context-dependent
(Ferguson, 2009). However, the numerical size generated is often much larger (i.e., >1)

41

than the magnitude of psychological research effect sizes. This discrepancy furthers the
doubt of efficacious psychological tests to medical tests among consumers. However,
contemporary studies indicate that a test of psychological diagnosis and functioning
produces similar effect sizes to medical tests. This quantitative synthesis of literature will
serve as a powerful tool in utilizing neuropsychological tests for diagnosis and treatment.
Future information from this meta-analysis will likely benefit neuropsychologists
and their patients alike, as research indicates the decline of neuropsychological tests
despite their usefulness in diagnosis and treatment. This study holds promise in serving as
a powerful tool that examines the consistency of effects across medical and
neuropsychological test studies and assists both practitioners and scientists in determining
just how important these tests are. To date, the Meyer et al. (2001) review continues to be
the only synthesis of this literature.

2.7 Goals and Hypotheses
Goal One. The primary goal of this study was to compare the magnitude of the total
effect size across medical tests, medications for chronic disease, and neuropsychological
tests. That is, this goal sought to determine if there is a reliable difference in effect sizes
between medical tests, medications, and neuropsychological tests. In accordance with this
goal, it was hypothesized that:
1.1 Similar to findings reported from the Meyer et al. (2001) meta-analysis, effect
sizes across medical tests, medications for chronic disease, and
neuropsychological tests will not be significantly different.
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Goal Two. The second goal was to index the average effect size within the two domains
of medical interventions and technologies: neuroimaging and medications. In relation to
this goal, it was hypothesized that:
2.1 Effects associated with neuroimaging would result in larger effect sizes than
effects for medications for chronic disease.
Goal Three. The third goal of this study was to index the average effect size within the
two clinical groups assessed with neuropsychological tests. To address this goal, it was
hypothesized that:
3.1 Effects associated with neuropsychological tests for those diagnosed with AD
would be comparable to effects for those diagnosed with a TBI.
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CHAPTER III
METHODOLOGY

3.1 Study Identification
The formal search for prospective candidate articles was conducted using
Academic Search Complete in addition to the following adjunctive databases: PsycINFO,
PsycARTICLES, Embase, PubMed, CINAHL, ScienceDirect, and ProQuest Dissertations
& Theses. To build the search term, *effect size,* or *efficacy*, was combined with the
terms *test,* and *validity,* followed by the descriptors *neuropsych,* *cognition,*
*dementia,* *Alzheimer’s Disease,* head injury,*, and *diagnosis,* for
neuropsychological test efficacy to diagnose to Alzheimer’s Disease and TBI examined
in the study. To provide a reasonable overview of the evidence on medical testing, *effect
size,* or *efficacy*was combined with the terms *test,* and *validity,* followed by the
descriptors *neuroimaging,* *MRI,* *medication*, *memantine,* *cholinesterase
inhibitors,* *dementia,* *Alzheimer’s Disease,* *mild cognitive impairment,*
*diagnosis,* for each domain of medical test efficacy examined in the study. All
semantically related variants of these keywords were included (e.g., head injury →
acquired brain injury → traumatic brain injury → concussion → mild traumatic brain
injury → TBI → mTBI etc.) In addition, the search was filtered to only display articles
since 2016 from academic, peer-reviewed sources and the English language. Additional
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studies were identified using a snowballing method of identifying candidate studies from
reference sections of review papers and recent studies.

3.2 Study Selection Criteria
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines were followed in carrying out this project (Moher, Liberati,
Tetzlaff, Altman, & The PRISMA Group, 2009). As relevant to this study, the satisfied
PRISMA 2009 Checklist criteria/elements included (1) assigning an appropriate title to
this project as being a meta-analysis; (2) provision of a structured summary (abstract
included background, objectives, data sources, study eligibility criteria, total participants,
synthesis methods, results, limitations, and conclusions/implications); (3) in the
introduction, description of the rationale and objectives of the meta-analysis in the
introduction; (4) in the methods section, detailed description search criteria, (5)
information sources (i.e., databases), (6) search terms, (7) study selection/eligibility
criteria, (8) data collection/extraction procedure, (9) specific data elements coded, (10)
how bias was assessed (i.e., publication bias analyses), (11) summary of effect size
estimate and discussion of how effect sizes were combined, and (12) secondary analysis
plan (i.e., meta-regressions and subgroup analyses); (13) results section detailing final
study sample, (14) study characteristics, (15) presentation of appropriate statistics (i.e.,
combined effect sizes, confidence intervals, measures of heterogeneity), (16) publication
bias results, and (17) secondary analysis results; (18) a discussion section that
summarizes the meta-analyses findings, (19) limitations, and (20) conclusions (Moher et
al., 2009).
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Studies identified from database searches and secondary obtainment were
evaluated according to several criteria. According to the central goal of this study,
investigations must feature the inclusion of a clinical group (i.e., individuals with
dementia due to AD, MCI, TBI, and/or cardiovascular risk factors). Studies included
should also include a control group. Next, studies must employ one of the following tests
or treatments: a brain MRI in samples with a diagnosis of Alzheimer’s Disease,
medication for memory impairment (MCI or AD), aspirin for preventing or reducing the
risk of cardiovascular events, or neuropsychological tests in samples with a diagnosis of
AD or a TBI. Third, investigations must feature the inclusion of efficacy statistics,
including effect sizes, confidence intervals, sensitivity, specificity, and/or error rates that
reflect some analysis of cross-sectional and/or longitudinal analysis of differences
between clinical and healthy individuals and/or correlation coefficients of the overall
mean effect size relation. Finally, selected studies must provide sufficient descriptive
statistical information (e.g., mean, SD) for each group.

3.3 Procedure
After finalizing the study selection for analysis, essential information from each
was coded onto spreadsheets. To reduce bias and improve coding reliability, two trained
graduate psychology students independently re-evaluated studies based on the inclusion
criteria and coded them. The inter-coder agreement was examined and evaluated by a
third trained graduate student to observe the level of reliability and consistency of coding
between coders. All discovered discrepancies between coders were addressed on a case-
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by-case basis by the third coder and reviewed by the whole research team to ensure 100%
agreement across the final spreadsheet.
To appropriately evaluate each of the research aims, study information was
conceptually organized hierarchically. The highest tier of coding included the type of test
(i.e., neuroimaging, medication, or neuropsychological test). Next, subgroup diagnosis
(i.e., AD, MCI, TBI, or cardiovascular condition) was coded. In the next level of coding,
the outcome/measure utilized was coded for all studies to examine the breakdown of
common measures and domains assessed. Coding for reported statistical information,
specifically efficacy statistics reported, and descriptive information was obtained. Lastly,
demographic (i.e., mean age of control and clinical samples, mean years of education of
control and clinical samples, and % male) and study characteristics (i.e., cognitive
domain, brain region, type of medication) were coded for each study to allow for
subsequent moderation analyses (i.e., estimation of ‘third variable’ effects). This coding
paradigm resulted in two levels of analysis according to specificity, which ranged from
broad domain (i.e., neuroimaging, medication, or neuropsychological test) to the specific
diagnosis within each domain (e.g., AD or TBI for the neuropsychological test) with the
ability to examine moderating effects of several study/methodologic factors. The analysis
plan for primary and secondary (i.e., moderation) analyses is discussed below.

3.4 Data Analysis
Quantitative meta-synthesis of selected studies was performed using
Comprehensive Meta-Analysis (v3) software. To account for presumed heterogeneity
between and within studies, all analyses were modeled by way of random effects
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(Borenstein et al., 2009; Field & Gillett, 2010; Hunter & Schmidt, 2004). In general,
analysis of studies occurred across two levels of granularity such that effect sizes were
computed for (1) aggregated test or treatment grouplets (i.e., neuroimaging, medication,
or neuropsychological test) and (2) when feasible (i.e., k ≥ 2), at the level of individual
conditions within each domain (e.g., AD or TBI for the neuropsychological test). In
addition, in line with the random-effects model used for this study’s analyses, withingroup estimates of τ2 (i.e., the total variance between studies; Huedo-Medina et al., 2006)
were pooled (Higgins & Green, 2011). Stated differently, a common among-study
variance component across subgroups was assumed.
3.4.1 Effect Size Computation and Combination
The main index of effect size used in this study was Hedge’s g. Its computation
was based on available demographic, descriptive, and/or inferential statistics (Borenstein
et al., 2009). Ideally, Hedge’s g is optimally estimated using control and clinical sample
size (n), M, and SD. For the instances when studies did not report sufficient descriptive
statistical data (i.e., partial information), effect sizes were estimated using inferential
statistical information, including test statistics and p values (when non-specific p-values
were given, they were set to conservative defaults of .05 for significant results and .999
for non-significant results; Borenstein et al., 2009). Hedges’ g is analogous to
Cohen’s d in that their unit of measurement is in SDs. Unique to this meta-analytic metric
is its correction for study sample size, which functions to correct for possible
overestimation bias in study effect sizes (Zakzanis, 2001). Interpretation of
Hedges’ g followed the convention proposed by Cohen (1988), such that 0.2 is small, 0.5
is moderate, and 0.8 is large.
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For studies with complex data structures (i.e., multiple outcomes) that reported
multiple effect sizes, they were combined using the mean of the selected outcomes, and
the study was used as the unit of analysis. In other words, for studies in which subgroups
produced multiple effect sizes across multiple outcomes, effect sizes were not treated
independently (as the assumption of independence of outcomes would not be met) but
rather pooled/averaged (Raudenbush, 2009; Shadish & Haddock, 2009). Following
conservative recommendations from Borenstein et al. (2009), random-effects modeling
was used for all primary and secondary (i.e., moderation) analyses. In addition,
stratification of effect sizes by clinical aggregate enabled formal evaluation of all
hypotheses (i.e., indexing the effect size differences across and within each domain).
3.4.2 Assessing Heterogeneity
For all primary and sub-meta-analyses, heterogeneity of effect sizes was assessed
in several ways. Specifically, Cochran’s Q test was used to determine whether the degree
of observed between-study heterogeneity (i.e., true variation) was above or below
expectation based on within-study error (i.e., sampling error; Borenstein et al., 2009;
Higgins et al., 2003). Due to underlying statistical assumptions (i.e., the Q statistic’s
inherent comparison of observed heterogeneity to what is expected due to pure sampling
error in the theoretical distribution containing all possible studies), fixed-effects
modeling was used to estimate heterogeneity (Borenstein et al., 2009). Heterogeneity was
also examined through the I2 statistic, which broadly reflects the ratio of true
heterogeneity (i.e., variability due to true differences between studies) to total variation.
In other words, the I2 statistic provides an approximation of the proportion of observed
variance that reflects real differences in effect size (due to between-study differences as
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opposed to sampling error; Higgins et al., 2003). As I2 reflects a proportion or ratio, it is
multiplied by 100 in the default equation to present as a percentage (%)—the percentage
of between-study heterogeneity that reflects true heterogeneity (Huedo-Medina et al.,
2006). According to guidelines from Higgins and Thompson (2002), degree/proportion of
true heterogeneity derived from I2 is qualified as follows: 25% = small heterogeneity,
50% = medium heterogeneity, and 75% = large heterogeneity. Others have postulated
that any I2 value exceeding 75 is thought to reflect considerable heterogeneity (Higgins
& Green, 2011). Thus, a non-significant Q test and an I2 value of 0 would indicate that
effect sizes are broadly homogenous and that all observed between-study variability in
effect sizes is broadly due to sampling error (i.e., within-study error; Borenstein et al.,
2009; Huedo-Medina et al., 2006).
3.4.3 Assessing Publication Bias
At the broadest sense, the funnel plot of effect sizes (x-axis) distributed across
standard error (y-axis) was visually inspected for preliminary evidence of publication bias
(i.e., gross asymmetry toward the positive end of the x-axis; Sutton, 2009). In addition,
for each main and sub-meta-analysis with sufficient studies (i.e., k ≥ 3), Egger’s
regression intercept was examined to determine whether there was a linear relation
between effect size and standard error (Egger et al., 1997). A one-sided significance test
was used for these analyses as a positive relation between standard error and effect size is
particularly concerning for publication bias in the present study. Such a relation reflects a
systematic relation between study sample size (i.e., standard error) and effect size, with
smaller studies producing disproportionate large effect estimates (and the inverse true for
large sample studies; Sutton, 2009). Lastly, Duval and Tweedie’s (2000a, 2000b) trim-
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and-fill procedure was used to test and subsequently correct for publication bias. In
simple terms, this methodology remedies gross asymmetry in the funnel plot by imputing
missing studies (hypothetically due to publication bias) in the right field of the funnel plot
as well as trimming off studies (extreme outliers) on the left field of the funnel plot in
order to restore symmetry to the center of the funnel plot (Sutton, 2009). The Trim and
Fill procedure augments studies (i.e., imputation and trimming), resulting in an adjusted
combined effect size estimate and corrected funnel plot. The random-effects model was
used in searching for missing studies (Borenstein et al., 2009).
3.4.4 Assessing Continuous and Categorical Moderators
According to several authorities on meta-analysis, a minimum of 10 studies
should accompany each moderator variable characteristic being modeled (Borenstein et
al., 2009; Higgins & Green, 2011). This ideal was upheld as best as possible for the
current study, and exceptions were made on a minimal and outstanding basis (e.g., one to
two studies shy of the standard). Continuous and categorical moderators/covariates were
formally assessed with statistical methods at the domain-broad and domain-specific for
studies to maximize statistical power for each analysis. In addition, heterogeneity was
only further explored using these moderation analyses when prompted by analyses
showing significant between-study heterogeneity as assessed by Q and I2 (Higgins &
Green, 2011).
The moderating effect of continuous covariates were assessed using the metaregression procedure, where effect sizes are regressed upon covariates to determine
whether they predict significant heterogeneity/variance in effect sizes (Hedges & Pigott,
2004; Higgins & Green, 2011). This analysis allows for either single (i.e., univariate) or
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simultaneous (i.e., multivariate) examination of potential continuous moderators (Hedges
& Pigott, 2004). All regression analyses were modeled under random effects and
estimated using the method of moments approach (Raudenbush, 2009). The following
continuous moderators were coded for: clinical age (M), control age (M), education
clinical (M years), education control (M years), % male clinical, and % male control.
Continuous moderator pairs (e.g., clinical age and control age) were linked in order to
combine them into a superordinate covariate (e.g., age), but this procedure was only done
if each separate covariate had sufficient studies (i.e., k ≥ 10; Borenstein et al., 2009;
Higgins & Green, 2011). Thus, when continuous moderators had sufficient studies, they
were linked together and run simultaneously in a multivariate meta-regression model.
Finally, the following categorical moderator variables were coded: cognitive
domain (i.e., verbal learning and memory, visual learning and memory, language,
attention, working memory, processing speed, executive functioning, visuospatial skills,
motor skills, global cognition), brain region (i.e., cingulate cortex, cortical grey matter,
frontal lobe, hippocampus, occipital lobe, parietal lobe, temporal lobe, white matter
lesions, whole-brain volume), and type of medication (i.e., aspirin and medication for
dementia (i.e., donepezil or memantine). When there were enough studies (i.e., k ≥ 10
within each level of the categorical moderator), subgroup analysis was conducted to
formally analyze categorical variables using a group-by and compare function
(Borenstein et al., 2009; Higgins & Green, 2011). A Q statistic was used for pairwise
comparisons of effect sizes across levels of continuous moderator variables, and a
significant finding indicated a significant difference in combined effect sizes.
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3.5 Power Analysis
The literature addressing fundamental statistical power (i.e., 1 – β) questions
about meta-analyses is sparse. Because of the nature of meta-analysis research, unique
parameters determine the number of studies necessary for achieving satisfactory
statistical power. Examples of such parameters are heterogeneity between studies,
expected average effect size(s), and average per-group sample sizes of each study
(Valentine, Pigott, & Rothstein, 2010). Additionally, Meyer et al. (2001) did not apply a
power analysis to determine how many studies to include. Consistent with this research
and the primary purpose of this paper to compare well-known tests and technologies in
the medical and psychological literature, a power analysis was not included.
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CHAPTER IV
RESULTS

4.1 Study Characteristics
The initial search yielded 6,668 results and was reduced to 6,522 after removing
duplicate hits. Following the first screening phase, 6,240 records were excluded for
irrelevancy based on the abstract. Two hundred eighty-two studies were selected for an
in-depth review to determine eligibility. From these, 210 additional records were
excluded for the following reasons: no clinical or control group (k = 53); wrong
assessment tools used (k = 48); wrong outcomes (k = 28); wrong patient population (k =
32); insufficient statistical information/data provided (k = 26); and inappropriate study
type (k = 23). Four additional eligible studies were identified through reference sections
of other studies reviewed (i.e., snowballing). Following this detailed review of results, 72
studies satisfied inclusion criteria and were selected for meta-analysis, and coding yielded
681 effect sizes for extraction. Included studies by broad domain aggregate were as
follows: neuropsychology = 32, neuroimaging = 21, and medication = 19 (note: 5 studies
provided effect sizes for both neuropsychological and neuroimaging data for AD clinical
groups). Three TBI neuropsychological studies reported multiple groups based on injury
severity (Baum et al., 2017, Steward et al., 2017, Tulsky et al., 2017). Each group was
analyzed as an individual study with independent outcomes by TBI severity, increasing
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the total number of studies to 75. See Appendix A for a detailed flowchart of the study
selection process (and reasons for study exclusion).
Across the total sample of selected studies (k = 75, 681 effect sizes),
Hedge’s g was estimated with full statistical information (i.e., clinical/control M, SD,
and n) for 63 studies (84% of all included studies) and a total of 586 extracted effect sizes
(86% of all effect sizes). When only partial statistical information was available, effect
sizes (Hedge’s g) were estimated under the following alternative circumstances: p-values
and clinical/control n (k = 4, 31 effect sizes) and clinical/control events and
clinical/control n (k = 10, 64 effect sizes). In the broadest sense, only 4% (31) of all the
included effect sizes were extracted under the crudest conditions—when papers provided
minimum statistical information for effect size estimation: p-values and
clinical/control n. Alternatively stated, 96% (650) of the total number of effect sizes
extracted from included studies provided complete (i.e., M, SD, and n for clinical and
control groups) or near-complete (e.g., events and sample sizes for both groups),
statistical information for effect size (Hedge’s g) estimation. The more statistical
information provided, the fewer assumptions are made in back-interpolating effect sizes
(Borenstein et al., 2009).

4.2 Broad-Domain Findings
Seventy-five studies (including independent subgroups within studies reported
above), yielding 681 unique effect sizes, were represented in the primary meta-analysis
(i.e., comparing effect sizes across domains: neuropsychological tests, neuroimaging, and
medications). There were sufficient studies to determine whether effect sizes differed
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across domains. Analysis revealed that combined effect sizes significantly differed as a
function of broad-domain findings [Q(2) = 78.081, p < .001]. See Figure 1 for visual
plot of this analysis.

Group by
Comparison

Hedges's g and 95% CI
Hedges's
g

Lower
limit

Upper
limit

Medication

-0.032

-0.314

0.251

Neuroimaging

-1.550

-1.830

-1.271

Neuropsychology

-1.477

-1.679

-1.275

Overall

-1.022

-1.939

-0.105
-2.00

-1.00

0.00

1.00

2.00

Figure 1. Subgroup analysis of studies across broad-domain aggregates.

According to pairwise comparisons, the neuroimaging aggregate combined effect
size [Hedges g = -1.670] was not significantly different than the neuropsychological test
efficacy [Hedges g = -1.548; Q(1) = 0.213, p = 0.644] but was significantly greater than
the medication test efficacy [Hedges g = -0.030; Q(1) = 104.006, p <0.001]. Further,
neuropsychological tests aggregate combined effect size [Hedges g = -1.468] was also
significantly greater than medication test efficacy [Hedges g = -0.032; Q(1) = 73.358, p
<0.001]. More detailed information on these comparisons is displayed below. See Table 1
for full subgroup analysis results. Below, domain-specific findings are displayed.
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Table 1.
Categorical Moderators for Broad Domain Studies
Categorical Moderator (k)
Broad Domain (78)g
Neuroimaging vs. Neuropsychological
Neuroimaging vs. Medication
Neuropsychological vs. Medication

Q
78.08
0.21
104.01
73.36

df
2
1
1
1

p
<.001
0.644
<.001
<.001

Pairwise
--MRI = Neuropsych
MRI > Meds
Neuro > Meds

4.3 Neuroimaging Aggregate Findings
Across the 21 studies examining brain MRIs between clinical (n = 1695) and
control (n = 1507) samples, 171 effect sizes were extracted for analysis. Meta-analysis
resulted in a significant large, combined effect size [Hedge’s g = -1.623, 95% CI = -1.973
to -1.273, p < .001]. Specifically, clinical samples diagnosed with Alzheimer’s Disease
had greater atrophy across brain regions than controls (see Figure 2). There was a
significant degree of between-study heterogeneity [Q(21) = 298.655, p < .001, I2 =
93.303]. Visual inspection of the funnel plot indicated that two studies (Machado et al.,
2020 and Park et al., 2017) with smaller sample sizes yielded larger (in the negative
direction), more unstable effect sizes, and perhaps should be interpreted with caution.
Similarly, Egger’s regression intercept [t(19) = 3.52, p(one-tailed) = .001] indicated
significant publication bias (see Figure 3). However, the Trim and Fill procedure did not
identify any studies likely missing due to publication bias.
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Figure 2. Forest plot for neuroimaging studies.

Figure 3. Funnel plot of standard error by Hedge’s g for neuroimaging studies.
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For broad neuroimaging studies, multivariate meta-regressions were performed on
the following variables with sufficient studies for linking: age (k = 21), education (k =
13), and sex (k = 19). Age [Q(2) = 5.18, R2 = .00, p = .0750], education [Q(2) = 4.59, R2
= .00, p = 0.1007], nor sex [Q(2) = 1.65, R2 = .00, p = .4374] were statically significant.
Education trended toward statistical significance but did not account for much variance.
Specifically, analyses indicated that clinical education [β = 0.403, SE = 0.189, z = 2.13, p
= 0.033] was a significant positive predictor of effect sizes. Namely, studies with more
educated clinical groups yielded greater effect sizes. See Table 2 for full meta-regression
analysis results. Meta-regression plot for the significant education analysis is displayed
on Figure 4.

Table 2.
Meta-Regressions for Continuous Variables in Neuroimaging Studies
Variable (k)

β

R2

a

SE

z

p

Age (21)
Clinical Age (21)
-.038
.038
-0.99
.32
< .01
Control Age (21)
-.066
.038
-1.75
.08
b
Education (13)
Clinical Education (13)
.403
.189
2.13
.03
<.01
Control Education (13)
-.380
.235
-1.62
.11
c
Sex (19)
% Male Clinical (19)
-.027
.022
-1.27
.20
< .01
% Male Control (19)
.016
.024
0.64
.52
a
b
c
Note. Q(2) = 5.18, p = .0750. Q(2) = 4.59, p = 0.1007. Q(2) = 1.65, p = .4374.
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Figure 4. Regression of Hedge’s g onClinical
clinical
education for neuroimaging studies.
Education

There were insufficient studies to formally examine the moderating effect of brain
region measurement on MRI effect sizes. While comparisons could not be made, there
were enough studies to report on effect sizes for the following brain region measurement
between clinical and control groups. Meta-analysis on 17 studies measuring hippocampus
resulted in a significant large, combined effect size [Hedge’s g = -2.458, 95% CI = -3.040
to -1.875, p < .001]. There was a significant degree of within subgroup (hippocampus
measurement) heterogeneity [Q(16) = 410.586, p < .001, I2 = 96.103]. Nine studies
measuring temporal lobe resulted in a significant large, combined effect size
[Hedge’s g = -1.741, 95% CI = -2.333 to -1.249, p < .001]. There was a considerable
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degree of within subgroup heterogeneity [Q(8) = 113.563, p < .001, I2 = 92.955]. See
Table 3 for full subgroup analysis results.

Table 3.
Subgroup, Combined Effect Size, and Heterogeneity Statistics for Brain Regions Measured
# es (k) Hedge's g (p)
95% CI
Q (p)
I2
Aggregate (n)
Hippocampus (1015)
Temporal Lobe (990)

48 (17)
34 (9)

-2.46 (< .001)
-1.74 (< .001)

Total (1372)a
82 (19) -2.14 (< .001)
Note. # es = Number of Effect Sizes.
a
Controls = 1405.

-3.04- (-)1.88
-2.33- (-)1.25

410.59 (< .001)
113.56 (< .001)

96.10
92.96

-2.61- (-)1.68 389.506(< .001)

95.38

4.4 Neuropsychological Tests Aggregate Findings
Across the 40 studies examining neuropsychological tests between clinical (n =
2161) and control (n = 2605) samples, 331 effect sizes were extracted for analysis. Metaanalysis resulted in a significant large, combined effect size [Hedge’s g = -1.563, 95% CI
= -1.895 to -1.230, p < .001]. Specifically, clinical samples (combined TBI and AD
groups) had worse performance on neuropsychological tests compared to controls (see
Figure 5). According to pairwise comparisons, the AD neuropsychological test effect
size [Hedges g = -2.213] was significantly different than the TBI neuropsychological test
efficacy [Hedges g = -0.649; Q(1) = 42.821, p = 0.000]. There was a significant degree
of between-study heterogeneity [Q(39) = 860.715, p < .001, I2 = 95.469]. Visual
inspection of the funnel plot indicated that one study (Reas et al., 2017) with a smaller
sample size yielded a significantly larger (in the negative direction), more unstable effect
size and perhaps should be interpreted with caution. Similarly, Egger’s regression
intercept [t(38) = 2.60, p(one-tailed) = .007] indicated significant publication bias (see Figure
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6). However, the Trim and Fill procedure did not identify any studies likely missing due
to publication bias.

Figure 5. Forest plot for neuropsychological studies.
Note. “i” after an article denotes multiple comparisons used within study.
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Figure 6. Funnel plot of standard error by Hedge’s g for broad neuropsychological
studies.

For broad neuropsychological test studies, multivariate meta-regressions were
performed on the following variables with sufficient studies for linking: age (k = 37),
education (k = 31), and sex (k = 30). Age accounted for a moderate portion of true
heterogeneity between neuropsychological test studies age [Q(2) = 34.78, R2 = .47, p
<.001]. Within this model, analyses indicated that neither clinical age [β = -0.044, SE =
0.0316, z = -1.41, p = 0.1590] nor control age [β = 0.0072, SE = 0.0341, z = 0.21, p =
0.8338] were individually significant predictors of effect size. Sex accounted for a small
portion of true heterogeneity between neuropsychological test studies age [Q(2) = 8.48,
R2 = .22, p = 0.0143]. Within this model, analyses indicated that neither clinical sex [β =
0.0167, SE = 0.0127, z = 1.31, p = 0.1898] nor control sex [β = 0.0129, SE = 0.0111, z =
1.16, p = 0.2473] were individually significant predictors of effect size. Education was
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not statistically significant [Q(2) = 3.11, R2 = .23, p = 0.2111]. See Table 4 for full metaregression analysis results.

Table 4.
Meta-Regressions for Continuous Variables in Neuroimaging Studies
Variable (k)

β

R2

SE

z

p

a

Age (37)
Clinical Age (37)
-.044
.032
-1.41
.16
.47
Control Age (37)
-.007
.034
.21
.83
b
Education (28)
Clinical Education (31)
.286
.165
.78
.43
.23
Control Education (29)
-.281
.164
-.95
.34
c
Sex (36)
% Male Clinical (36)
.017
.013
1.31
.19
.22
% Male Control (38)
.013
.011
1.16
.25
a
b
c
Note. Q(2) = 34.78, p <.001. Q(2) = 0.98, p = 0.6138. Q(2) = 8.48, p = 0.0143.

4.4.1 Neuropsychological Tests for Alzheimer’s Disease
Across the 20 studies examining neuropsychological tests between Alzheimer’s
Disease dementia (n = 1144) and control (n = 1524) samples, 161 effect sizes were
extracted for analysis. Meta-analysis resulted in a significant large effect size [Hedge’s g
= -2.483, 95% CI = -2.906 to -2.059, p < .001]. Specifically, clinical samples diagnosed
with AD had worse performance on neuropsychological tests than controls (see Figure
7). There was a significant degree of between-study heterogeneity [Q(19) = 280.975, p <
.001, I2 = 93.238]. Visual inspection of the funnel plot indicated that one study (Reas et
al., 2017) with a smaller sample size yielded a significantly larger (in the negative
direction), more unstable effect size, and perhaps should be interpreted with caution.
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Similarly, Egger’s regression intercept [t(18) = 2.40, p(one-tailed) = .013] indicated
significant publication bias (see Figure 8). However, the Trim and Fill procedure did not
identify any studies likely missing due to publication bias.

Figure 7. Forest plot for AD neuropsychological studies.
Note. “i” after an article denotes multiple comparisons used within study.
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Figure 8. Funnel plot of standard error by Hedge’s g for AD neuropsychological studies.

For AD neuropsychological studies, multivariate meta-regressions were
performed on the following variables with sufficient studies for linking: age (k =20),
education (k = 14), and sex (k = 19). Education accounted for a small portion of true
heterogeneity between neuropsychological test studies [Q(2) = 8.66, R2 = .15, p =
0.0132], though neither control education [β = -0.1098, SE = 0.1574, z = -0.70, p =
0.4854] or clinical education [β = -0.0883, SE = 0.1689, z = -0.52, p = 0.6012] alone were
statistically significant. Neither age [Q(2) = 0.21, R2 = .00, p = 0.9016] nor sex [Q(2) =
3.13, R2 = .00, p = 0.2090] was statistically significant. See Table 5 for full metaregression analysis results.
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Table 5.
Meta-Regressions for Continuous Variables in AD Neuropsychology Studies
Variable (k)

β

R2

SE

z

p

a

Age (20)
Clinical Age (20)
-.029
.082
-.35
.73
< .01
Control Age (20)
.023
.052
.45
.65
Educationb (14)
Clinical Education (15)
-.088
.169
-.52
.60
.15
Control Education (14)
-.110
.157
-.70
.49
c
Sex (19)
% Male Clinical (19)
-.044
.026
-1.71
.09
< .01
% Male Control (20)
.003
.021
.12
.90
a
b
c
Note. Q(2) = 0.21, p = 0.9016. Q(2) = 8.66, p = 0.0132. Q(2) = 3.13, p = 0.2090.

There were insufficient studies to formally examine the moderating effect of the
cognitive domain on neuropsychological test efficacy within an AD population. While
comparisons could not be made, there were enough studies to report on effect sizes for
the following cognitive domains between clinical and control groups. Meta-analysis on
14 studies measuring executive functioning resulted in a significant large effect size
[Hedge’s g = -2.011, 95% CI = -2.458 to -1.563, p < .001]. There was a significant
degree of heterogeneity [Q(13) = 175.280, p < .001, I2 = 92.583]. Ten studies measuring
language resulted in a significant large effect size [Hedge’s g = -2.596, 95% CI = -3.998
to -1.194, p < .001]. There was a large degree of within subgroup heterogeneity [Q(9) =
591.676, p < .001, I2 = 98.479]. Fifteen studies measuring verbal learning and memory
resulted in a significant large effect size [Hedge’s g = -3.642, 95% CI = -4.368 to -2.915,
p < .001]. There was a large degree of within subgroup heterogeneity [Q(14) = 328.202,
p < .001, I2 = 95.734]. See Table 6 for full subgroup analysis results.
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Table 6.
Subgroup, Combined Effect Size, and Heterogeneity Statistics for Cognitive Domains in AD
Neuropsychology Studies
# es (k) Hedge's g (p)
95% CI
Q (p)
I2
Aggregate (n)
Executive Functions
(687)
51 (14) -2.01 (< .001) -2.46- (-)1.56 175.28 (< .001) 92.58
Language (419)
16 (10) -2.60 (< .001) -4.00- (-)1.19 591.68 (< .001) 98.48
Verbal Learning and
Memory (847)
53 (15) -3.64 (< .001) -4.37- (-)2.92 328.20 (< .001) 95.73
Total (1038)a
120 (20) -2.62 (< .001)
Note. # es = Number of Effect Sizes.
a
Controls = 1387.

-3.70- (-)2.08

442.32 (< .001)

95.70

4.4.2 Neuropsychological Tests for TBI
Across the 20 studies examining neuropsychological tests between those with a
TBI (n = 1016 and control (n = 1081) samples, 170 effect sizes were extracted for
analysis. Meta-analysis resulted in a significant medium effect size [Hedge’s g = -0.613,
95% CI = -0.804 to -0.442, p < .001]. Specifically, clinical samples diagnosed with a TBI
had worse performance on neuropsychological tests compared to controls (see Figure 9).
There was a moderate degree of between-study heterogeneity [Q(19) = 71.671, p < .001,
I2 = 73.490]. Visual inspection of the funnel plot indicated overall symmetry, with one
study (Ghawami et al., 2017) with a smaller sample size yielded a slightly larger (in the
negative direction), more unstable effect size, and perhaps should be interpreted with
caution. Similarly, Egger’s regression intercept [t(18) = 2.00, p(one-tailed) = .03] indicated
significant publication bias (see Figure 10). However, the Trim and Fill procedure failed
to identify any studies likely missing due to publication bias.
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Figure 9. Forest plot for TBI neuropsychological studies.
Note. “i” after an article denotes multiple comparisons used within study.

Figure 10. Funnel plot of standard error by Hedge’s g for TBI neuropsychological studies
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For TBI neuropsychological studies, multivariate meta-regressions were
performed on the following variables with sufficient studies for linking: age (k = 17),
education (k = 10), and sex (k = 11). Education was statistically significant in explaining
a moderate degree of heterogeneity [Q(2) = 12.11, R2 = .50, p =0.0023], but neither
clinical [β = 0.3364, SE = 0.1745, z = 1.93, p = 0.0538] nor control [β = -0.0898, SE =
0.1779, z = -.51, p = 0.6135] groups alone were statistically significant. Neither age [Q(2)
= .94, R2 = .00, p = 0.6251] nor sex [Q(2) = 5.52, R2 = .04, p <.0632] was significant in
explaining observed heterogeneity between studies. See Table 7 for full meta-regression
analysis results.

Table 7.
Meta-Regressions for Continuous Variables in TBI Neuropsychology Studies
Variable (k)

β

R2

SE

z

p

a

Age (17)
Clinical Age (17)
.033
.034
.97
.33
< .01
Control Age (18)
.032
.036
-.89
.38
Educationb (14)
Clinical Education (16)
.336
.175
1.93
.05
.50
Control Education (15)
-.089
.178
-.51
.61
c
Sex (17)
% Male Clinical (17)
-.023
.012
-1.95
.05
.04
% Male Control (18)
-.002
.007
.26
.80
a
b
c
Note. Q(2) = .94, p = 0.6251. Q(2) = 12.11, p =0.0023. Q(2) = 5.52, p <.0632.

Subgroup analysis to examine combined effect size differences across TBI
severity was not conducted, as the number of studies fell below the recommended k of
10, (Mild TBI k = 6, Mild/Moderate k = 1, Moderate/Severe k = 5, Combined Severity k
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= 6). There were insufficient studies to formally examine the moderating effect of the
cognitive domain on neuropsychological test efficacy within a TBI population. While
comparisons could not be made, there were enough studies to report on effect sizes for
the following cognitive domains between clinical and control groups. Meta-analysis on
18 studies measuring executive functioning resulted in a significant moderate effect size
[Hedge’s g = -0.685, 95% CI = -0.880 to -0.491, p < .001]. There was a moderate degree
of heterogeneity [Q(17) = 65.728, p < .001, I2 = 74.136]. Thirteen studies measuring
processing speed resulted in a significant moderate, combined effect size [Hedge’s g = .645, 95% CI = -0.879 to -0.411, p < .001]. There was a moderate degree heterogeneity
[Q(12) = 54.789, p < .001, I2 = 78.098]. See Table 8 for full subgroup analysis results.

Table 8.
Subgroup, Combined Effect Size, and Heterogeneity Statistics for Cognitive Domains in
TBI Neuropsychology Studies
# es (k) Hedge's g (p)
95% CI
Q (p)
I2
Aggregate (n)
Executive Functions
(1001)
68 (18) -.69 (< .001)
-.88- (-).49 65.728 (< .001) 74.14
Processing Speed
(774)
28 (13) -.65 (< .001)
-.88- (-).41
54.79 (< .001) 78.10
Total (1001)a
96 (18) -.69 (< .001)
Note. # es = Number of Effect Sizes.
a
Controls = 1048.

-89- (-).49

69.73 (< .001)

75.62

4.5 Medication Aggregate Findings
Across the 19 studies examining medications between clinical (n = 32333) and
control (n = 39122) samples, 178 effect sizes were extracted for analysis. Meta-analysis
resulted in a small, nonsignificant effect size [Hedge’s g = -.024, 95% CI = -0.105 to
0.058, p = 0.570]. There was a moderate degree of between-study heterogeneity [Q(17)
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= 41.862, p < .001, I2 = 57.002]. There was no indication of publication bias across these
studies based on Egger’s regression intercept [t(17) = 0.42, p(one-tailed) = .34], visual
inspection of the funnel plot (see Figure 11), and the Trim and Fill procedure.

Funnel Plot of Standard Error by Hedges's g
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Figure 11. Funnel plot of standard error by Hedge’s g for medications

For broad medication studies, multivariate meta-regressions were performed on
the following variables with sufficient studies for linking: age (k = 16) and sex (k = 16),
as there was not sufficient studies for education. Neither age [Q(2) = 0.41, R2 = .00, p =
0.8153] nor sex were statistically significant [Q(2) = 0.08, R2 = .00, p = 0.9624]
contributors to heterogeneity found across medication studies. See Table 9 for full metaregression analysis results.
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Table 9.
Meta-Regressions for Continuous Variables in Broad Medication Studies
β

R2

Variable (k)

SE

z

p

a

Age (16)
Clinical Age (16)
.001
.038
.04
< .01
Control Age (17)
-.008
.034
-.24
Sexb (16)
% Male Clinical (16)
-.007
.024
-.21
< .01
% Male Control (17)
.007
.024
.28
a
b
Note. Q(2) = 0.41, p = 0.8153. Q(2) = 0.08, p = 0.9624.

.97
.81
.79
.78

4.5.1 Medication for Memory Impairment Findings
Across the 10 studies examining medication for memory impairment only
between clinical (n = 1777) and control (n = 1568) samples, 126 effect sizes were
extracted for analysis. Meta-analysis resulted in a small, nonsignificant effect size
[Hedge’s g = -.052, 95% CI = -0.237 to 0.133, p = 0.580] and degree of heterogeneity
was moderate [Q(8) = 34.139, p = 0.000, I2 = 73.637]. Specifically, there was no
difference in performance on cognitive tests for those diagnosed with MCI or AD who
were prescribed medication compared to those who were not (see Figure 12). There was
no indication of publication bias across these studies based on Egger’s regression
intercept [t(8) = 0.51, p(one-tailed) = .31], visual inspection of the funnel plot (see Figure
13), and the Trim and Fill procedure.
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Figure 12. Forest plot for memory impairment medication studies.

Figure 13. Funnel plot of standard error by Hedge’s g for memory impairment
medication studies
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There were insufficient studies to formally examine the moderating effect of types
of medication prescribed for memory impairment (cholinesterase inhibitors and
memantine) nor to formally examine the impact of medication on measures of cognitive
functioning due to the number of studies falling below the recommended k of 10
(cholinesterase inhibitors k = 4; memantine k = 3). Further, due to an insufficient number
of studies (i.e., no continuous moderators had valid data for ≥10 studies), metaregressions were not performed to further evaluate sources of heterogeneity.
4.5.2 Aspirin Findings
Across the nine studies examining aspirin for cardiovascular events only between
clinical (n = 30556) and control (n = 37554) samples, 52 effect sizes were extracted for
analysis. Meta-analysis resulted in a small, nonsignificant effect size [Hedge’s g = .017,
95% CI = -0.025 to 0.060, p = 0.426] and degree of heterogeneity was small [Q(8) =
1.202, p = 0.997, I2 = 0.000]. Specifically, there was no difference in the number of
cardiovascular events between those prescribed aspirin and those who were not (see
Figure 14). There was no indication of publication bias across these studies based on
Egger’s regression intercept [t(7) = 0.75, p(one-tailed) = .24], visual inspection of the funnel
plot (see Figure 15), and the Trim and Fill procedure. Further, due to an insufficient
number of studies (i.e., no continuous moderators had valid data for ≥10 studies), metaregressions were not performed to further evaluate sources of heterogeneity.
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Figure 14. Forest plot for Aspirin studies.
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Figure 15. Funnel plot of standard error by Hedge’s g for Aspirin for cardiovascular
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CHAPTER V
DISCUSSION

The past 50 years have brought drastic changes to healthcare and an emphasis on
cost management and efficiency. This negatively affected the use of lengthy traditional
comprehensive psychological assessments (Piotrowski, 1999; Piotrowski, 2017).
Additionally, there has been a general increase in medical literacy due to the internet and
expanded access to healthcare (Kimmerle et al., 2015; Sapp et al., 2013). Unfortunately,
these advances have been preferentially associated with “medicine” and have culturally
resulted in the faulty assumption that medical tests provide more reliable or valid data
than psychological assessments (Chambers, 2014). However, in an examination of 144
meta-analyses and authoritative papers, the APA PAWG found that while psychological
and medical tests have varying degrees of validity, validity coefficients for many
psychological tests were indistinguishable from those of medical tests (Meyer et al.,
2001). Specifically, the workgroup concluded that many gold standard psychological
tests work just as well as medical tests to detect the same outcome, such as
neuropsychological testing detecting dementia on par with MRI (Meyer et al., 2001).
This dissertation aimed to replicate the findings of the PAWG with an emphasis on the
efficacy of common neuropsychological tests, neuroimaging, and medication studies
published in the last five years.
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The scope of this meta-analysis was constrained to the three following main study
questions: Q1. Is there a significant difference in effect sizes between medical tests,
medications, and neuropsychological tests? Q2. Is there a significant difference in effect
sizes within medical interventions and technologies? Q3. Is there a significant difference
in effect sizes of neuropsychological tests between different clinical groups? This
comprehensive meta-analysis of studies sought to address these central study questions
with three overarching goals: (1) index the broad effect size of the difference in medical
tests, medications, and neuropsychological tests; (2) determine the impact of measured
brain regions and type of medication has on effect sizes for neuroimaging, and
medication studies, respectively; and (3) determine the impact of clinical group and
cognitive domains measured within neuropsychological studies. With the exception of
the first goal (i.e., the broad domain comparison), domain-specific studies were metaanalyzed separately to accomplish the other study goals, including finer subgroup
analyses.

5.1 Goal One: Are Effect Sizes Different Between Neuropsychological Tests, Medical
Tests, and Medications?
The first overarching goal of this study was to index the magnitude of effect sizes
across broad-domain findings for neuropsychological tests, neuroimaging, and
medication. An a priori directional prediction was made that no significant difference
would be observed across the three broad domains. Meta-analysis of all included studies
partly confirmed this hypothesis. There was a statistically non-significant difference
between the large effect sizes obtained for neuroimaging (Hedges g = -1.670) and
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neuropsychological test efficacy [Hedges g = -1.548; Q(1) = 0.213, p = 0.644]. However,
there was a significant difference between neuroimaging and medication test efficacy
[Hedges g = -0.030; Q(1) = 104.006, p <0.001], as well as neuropsychological tests and
medication test efficacy [Q(1) = 73.358, p <0.001]. Stated differently, the diagnostic
efficacy of neuroimaging and neuropsychological tests were both substantial and nonsignificantly different from one another. The treatment efficacy of included medications
was non-significant and substantially smaller than the other two broad domains.

5.2 Goal Two: Do Moderating Factors Impact Effect Sizes of Medical Domains?
The second broad goal of this study (G2) was to study the possible factors
impacting test efficacy across selected medical diagnostics and treatments. For H2.1, it
was broadly hypothesized that neuroimaging studies would yield larger effect sizes than
medication studies. As mentioned in the broad-domain findings, the effect size for broad
medications was nonsignificant. Subgroup analysis revealed that both medication for
memory impairment (Hedges g = -.052) and aspirin (Hedges g = .017) yielded small,
nonsignificant effect sizes. Therefore, hypothesis two was confirmed, such that effect
sizes for neuroimaging studies (Hedges g = -1.623) were larger than for medication
studies (Hedges g = -.024).
Next, a significant large degree of between-study heterogeneity was observed in
neuroimaging studies (I2 = 93.30), respectively, reflecting considerable “true”
heterogeneity (i.e., true between-study differences), that is beyond what would be
expected by sampling error alone. This finding warranted further investigation of
heterogeneity using coded continuous and categorical moderators. Meta-regression
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analyses indicated that clinical group education level (p = 0.033) trended toward
statistical significance, but education overall did not account for much variance (R2 =
.00). Age and sex did not account for any variance in neuroimaging effect size findings.
This pattern of meta-regression findings may demonstrate the cognitive reserve effect of
education on brain atrophy, at least in the early stages of decline (Nyberg et al., 2021).
Regarding categorical moderators, there were insufficient studies within each
domain to conduct formal analyses of measurements of each brain region. However, there
were sufficient studies to analyze effect sizes for some specific brain regions measured
by neuroimaging. A meta-analysis of 17 studies measuring the hippocampus resulted in a
significant large, combined effect size [Hedge’s g = -2.458]. Nine studies measuring the
temporal lobe resulted in a significant large, combined effect size [Hedge’s g = -1.741].
These findings are consistent with hippocampal atrophy as one of the most established
and validated core biomarkers of AD and disease progression (Pini et al., 2016), as well
as temporal lobe atrophy being one of the earliest changes seen in the brains of those with
AD (Visser et al., 1999).

5.3 Goal Three: Do Moderating Factors Impact Effect Sizes of
Neuropsychological Tests?
The final goal was to index the magnitude of effect sizes between the two clinical
groups within the neuropsychological test studies. An a priori directional prediction was
made that no significant difference would be observed between neuropsychological tastes
for those with AD versus those with a TBI. Meta-analysis of included studies did not
support this hypothesis, such that AD neuropsychological test effect size [Hedges g = -
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2.213] was significantly different than the TBI neuropsychological test efficacy
[Hedges g = -0.649; Q(1) = 42.821, p = 0.000]. There was a significant large degree of
between-study heterogeneity observed in neuropsychological studies (I2 = 95.47),
respectively, reflecting considerable “true” heterogeneity (i.e., true between-study
differences) that is beyond what would be expected by sampling error alone. This finding
warranted further investigation of heterogeneity using coded continuous and categorical
moderators.
Meta-regression analyses indicated that age accounted for the greatest amount of
true heterogeneity (R2 = .47), followed by sex (R2 = .22); however, neither clinical nor
control age or sex were independently significant predictors of the observed variance.
These meta-regression models were run separately due to power limitations. This pattern
of meta-regression findings may demonstrate an increased risk of AD with age (2022
Alzheimer’s disease facts and figures, 2022) that is being captured by neuropsychological
tests. While education was not significant at the broad neuropsychological domain level,
it was a significant predictor of observed variance for both the AD studies (R2 = .15) and
TBI studies (R2 = .50). However, neither clinical nor control education levels were
independently significant predictors of observed variance for neither AD nor TBI studies.
Additionally, the cognitive reserve effect of education has been consistently associated
with healthier cognitive aging, reduced risk/rate of cognitive decline/dementia, and a
proxy for cognitive endowment/brain reserve (Stern, 2009).
There were insufficient studies within each domain regarding categorical
moderators to conduct formal analyses of assessed cognitive domains. However, there
were sufficient studies to analyze effect sizes for some cognitive domains assessed by
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neuropsychological tests. Within the AD clinical group, a meta-analysis of 14 studies
measuring executive functioning resulted in a significant large, combined effect size
[Hedge’s g = -2.011], and 10 studies measuring language skills resulted in a significant
large, combined effect size [Hedge’s g = -2.596], and 15 studies measuring verbal
learning and memory skills resulted in a significant large, combined effect size
[Hedge’s g = -3.642]. These results are consistent with known neuropsychological profile
of patients with AD, with the earliest impairments seen in verbal learning and memory,
with impairment in other areas as the disease progresses, including executive functioning
and language skills (Weintraub, Wicklund, & Salmon, 2012). A meta-analysis of 18
studies measuring executive functioning within the TBI clinical group resulted in a
significant moderate combined effect size [Hedge’s g = -.685], and 13 studies measuring
processing speed resulted in a significant moderate combined effect size [Hedge’s g = .645]. These results are consistent with the known neuropsychological profile of patients
with TBI, with impairments in executive functioning (i.e., cognitive flexibility, planning,
and inhibition), processing speed, and attention (Azouvi et al., 2017; Donders & Levitt,
2012).

5.4 Limitations
While this project had a number of strengths inherent in meta-analyses, it was not
without limitations. First, contrary to the PRISMA Checklist (Moher et al., 2009), this
study was not formally registered, and, aside from statistical analyses examining
publication bias, study quality was not indexed. Incorporating a study quality index could
have been utilized in the selection criteria (e.g., excluding studies falling below a certain
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threshold on a study quality measure) to strengthen inclusion/exclusion criteria.
Additionally, having a study quality index as a moderator could have been used to
determine whether effect sizes varied as a function of study quality. However, the current
project’s methodological strengths of using multiple independent coders, stringent
inclusion criteria, and thorough analysis of publication bias mitigated this limitation.
Next, while valid reasons were considered for not including unpublished
manuscripts/data, doing so may have inflated the risk of publication bias. Nevertheless,
while both neuroimaging and neuropsychological test domains yielded significant
evidence of publication bias, this was most likely due to a select number of studies with
small sample sizes, as analyses failed to identify any studies likely missing due to
publication bias.
The relatively small number of medication studies (especially within the
medication subgroups) compared to the other two domains and the high heterogeneity
seen between studies adversely impacted statistical power. Because of this, formal
analysis of moderators for medication studies was only conducted at the broad level (i.e.,
across all medications) and limited to the continuous variables—there were insufficient
medication studies within the two subgroups for categorical variables to be formally
analyzed. Beyond medication studies, there were too few studies within each broad
domain to run categorical meta-regression on brain region-specific neuroimaging
findings or cognitive domain-specific neuropsychological test findings. It is worthy to
note that the limited number of studies is not due to sparse literature but instead was
limited by the inclusion criteria of research within the last five years. There was an
abundance of efficacy studies of aspirin and medications for memory impairment prior to
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2016 that were excluded from this meta-analysis to provide the most current update on
the existing literature across the three broad domains. Separate from power-limiting
moderator analyses, the relatively smaller number of studies in broad domains and
clinical subgroups reduces the generalizability/external validity of findings.
Prominent heterogeneity observed across analyses also compounded statistical
power. However, as stated above, the problem of insufficient studies (for certain subanalyses) greatly restricted the ability to explore such heterogeneity further. Using the
Cochrane Collaboration guidelines (Higgins et al., 2011) of a minimum of 10 studies for
each moderation characteristic modeled, heterogeneity could not be further explored (i.e.,
with moderation analyses) in several sub-groups/aggregates. Aside from the
neuropsychological tests for the TBI subgroup and medication domain, which still
yielded moderate heterogeneity, high heterogeneity was generally observed across all
analyses. Heterogeneity was especially high in broad domain neuroimaging and
neuropsychological studies, likely reflecting considerable methodological differences in
these studies. Meta-regressions indicated that age and sex, and to a lesser degree,
education accounted for a significant amount of this heterogeneity. Nevertheless, the lack
of studies precluded further analysis of sources of heterogeneity. Most broad and subanalyses resulted in significant combined effect sizes despite these limitations.

5.5 Implications and Future Directions
Notwithstanding the limitations listed above, the results of this dissertation made
a significant contribution by demonstrating the similar efficacy of neuropsychological
testing to equivalent medical diagnostics and treatments. In the broadest sense, this
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comprehensive meta-analysis offered an updated quantitative consensus for several
questions that the APA PAWG set out to explore in 2001. In addition, this dissertation
provided important insights into the efficacy of two of the most frequent patient requests:
diagnosis and treatment.
At a broad-domain level and consistent with the most important goal of this study
(G1), no significant difference was found between neuropsychological test studies and
neuroimaging studies in diagnostic efficacy. Additionally, there was a significant
difference between neuropsychological test studies and medication studies, such that
neuropsychological studies evidenced a greater, significant effect size. However, it is
important to note the relatively smaller number of studies within the medication domain,
though this was somewhat moderated by the large number of participants resulting from
medication clinical trials. Additionally, there was support for G2, as there was also a
significant difference between neuroimaging studies and medication studies, such that
neuroimaging studies evidenced a greater, significant effect size. This is consistent with
Meyer et al. (2001) findings that the correlational effect size of taking aspirin and a
subsequent cardiac event was much lower than the effect size for the use of MRI and
neuropsychological tests to differentiate between dementia and controls.
These findings not only replicate aspects of the Meyer et al. (2001) landmark
meta-analysis indicating no substantial difference in MRI and neuropsychological
assessment to diagnose AD but also provide evidence for the efficacy of
neuropsychological tests to diagnose TBI on par with neuroimaging. Interestingly, while
neuropsychological tests were significant for both clinical groups, there was no support
for the third goal (G3). There was a significant difference between the effect sizes
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between the two clinical groups. Neuropsychological tests to diagnose AD were
significantly larger than tests to diagnose TBI. This may, in part, be due to a difference in
the level of severity of AD versus TBI at the time of evaluation and/or battery of tests
administered.
Though the secondary meta-regression and subgroup analyses were not a central
focus of the study, they provided useful information. None of the continuous moderators
coded accounted for any significant proportion of variance for neuroimaging studies. This
suggests there are likely other moderating factors, such as the reliability of raters when
using visual assessment atrophy scales versus measurement software, which may warrant
further study. Research has found a significant difference in results based on the type of
software (Gronenschild et al., 2012) and independent or group of coders (Harpter et al.,
2015; Victoroff et al., 1994) when interpreting brain MRI data.
For broad neuropsychological studies, age and sex accounted for a significant
portion of the variance between studies, highlighting the overall lower age of and
predominantly male participants of the TBI studies. Further, education accounted for a
small to large amount of variability within both AD and TBI clinical groups. These
findings are consistent with cognitive reserve literature showing that higher educational
attainment is associated with general cognitive health, protection from cognitive
dysfunction, and slowed the progression of neurodegenerative cognitive decline (Stern,
2009). Further, when considering categorical moderators (i.e., specific cognitive
domains), results were consistent with significant research showing verbal learning and
memory difficulties among those with AD (Bäckman et al., 2005; Rabin et al., 2009).
However, findings also showed significant difficulties with executive functioning and
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language skills, which could represent mixed etiology of dementia, and/or later
progression of the disease. Future meta-analyses examining longitudinal
neuropsychological studies of AD and/or coding for the length of time since diagnosis
should be considered.
Finally, the medication studies yielded a nonsignificant result, both at the broaddomain level and across the two subgroups. While the relatively few studies certainly
impact this finding, this is moderated by a large number of participants in the clinical
trials. These results suggest that neither aspirin nor memory impairment medications
significantly reduce cardiac events or improve cognitive functioning. Daily aspirin has
been prescribed to prevent cardiac events or strokes since the 1970s; however, the US
Preventative Services Task Force (USPSTF) recently recommended that people ages 60
and older should not start taking a daily aspirin due to the risk of internal bleeding
cancels out the benefits of preventing heart problems (USPSTF, 2021). The current
findings are in line with the new guidelines and should be considered when determining
treatments for cardiac events. Conversely, Cochrane reviews for memory impairment
medication indicated that people with AD might experience small benefits in cognitive
functioning from donepezil (Birks & Harvey, 2018), demonstrate at least an initial
improvement in global cognition to galantamine (Loy & Schneider, 2007), had a slower
cognitive decline and ADLs with rivastigmine (Birks et al., 2015), and small clinical
benefit in global cognition in moderate to severe AD with memantine (McShane et al.,
2019). Of note, all studies used in this dissertation were published after the Cochrane
reviews and constitute a new contribution to this literature.
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The current findings have both experimental and clinical applicability. While the
vast majority of studies in this analysis provided means and standard deviations, resulting
in the same effect size (Hedges g) across domains, this is often not the case. Research on
test efficacy across the two disciplines often utilizes different statistics and is reported
differently by the media, leading to consumer confusion. In consideration of effect sizes
across fields, effect sizes seen in the social sciences are often very small (Rosnow, 2003),
and there is no agreement on what magnitude of effect is necessary to establish practical
significance (Ferguson, 2009). Conversely, the numerical size of medical test efficacy
effect sizes is often much larger (i.e., >1) than the magnitude of psychological research
effect sizes. This leads to difficulties in their interpretation and furthers the doubt of
efficacious psychological tests to medical tests among consumers. Future medical and
psychological research should consider providing full statistical information (i.e.,
clinical/control M, SD, and n) such that a common effect size can be generated, and a
more direct comparison can be made across domains.
In the case of clinical applicability, this quantitative synthesis of the literature
provides clinicians and consumers with convincing evidence that neuropsychological
tests are a reliable diagnostic tool for people with both acquired and neurodegenerative
brain disorders. There is strong evidence that the public generally overestimates the
effectiveness of medical technologies and interventions (Funk et al., 2019). However,
Meyer et al. (2001) found that psychological test validity was comparable to the validity
of medical tests. This updated meta-analysis drew from recent studies within specific
diagnostic domains and successfully replicated findings that the diagnostic efficacy of
neuropsychological tests was comparable to the diagnostic efficacy of neuroimaging. In
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contrast, effect sizes for well-known and commonly prescribed medications such as
aspirin and memory impairments were nonsignificant. The evidence supports the
diagnostic efficacy of both neuropsychological tests and neuroimaging, with less
evidence to support the treatment efficacy of the included medications.
This meta-analysis lends to the efficacy of neuropsychological tests for consumers
and provides a further argument for insurance re-valuation of neuropsychological
evaluations. Unfortunately, insurance coverage of comprehensive neuropsychological
assessments continues to decline, while most standard medical diagnostic tests, such as
MRIs for suspicion of dementia, are covered by insurance. However, research has found
that the cost of comprehensive neuropsychological assessments was less than the
standard costs of an MRI by approximately $1,500 (Kurniadi & Davis, 2021). Further,
research has found that neuropsychological evaluations significantly decrease healthcare
spending and utilization (Lichtenstein, Linnea, & Maerlender, 2018; Van Kirk et al.,
2013), potentially due to early identification and increased community support and
treatment (Barnett et al., 2014; Leibson et al., 2015). This research demonstrates that the
lower cost of neuropsychological tests, decreased long-term healthcare cost through early
neuropsychological evaluation and diagnosis, and comparable diagnostic efficacy
between MRI and neuropsychological tests found in the current study warrants continued
advocacy for a re-valuation of insurance coverage and reimbursement of
neuropsychological tests. This would reduce the financial burden of consumers
undergoing a neuropsychological evaluation and boost the incremental value of
neuropsychological tests in an evolving healthcare arena (Glen et al., 2020).
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The scope of the current study was broad. Important relations were not examined
to retain some semblance of focus and consistency with the original Meyer et al. (2001)
article. Particularly the relation between other commonly used medical imaging (e.g., CT
scans, fMRI, PET), other common presentations examined by neuropsychology (e.g.,
ADHD, stroke, movement disorders), and other commonly prescribed medications (e.g.,
hypertensive medications, statins, thyroid, diabetes, anti-depressants) would benefit from
further study. Given limited support for the coded moderators in contributing to the
observed heterogeneity between studies, future studies should consider other moderators,
such as time since diagnosis, comorbid diagnoses, and race and ethnicity. Finally, future
meta-analyses examining the comparable efficacy of neuropsychology and medical
diagnostic tools and treatments should consider analyzing longitudinal studies, as the
cross-sectional design of this meta-analysis limits the generalizability of the long-term
efficacy of these healthcare tools.
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Appendix A: Flow Chart of Study Screening and Selection

# of records identified through data base searching:
• EBSCO databases = 6,668

# of records after duplicates removed:
• EBSCO databases = 6522

# of identified records excluded based
on:
• Title = 3,848
• Abstract = 2,361
• Source Type = 31

# of records reviewed for inclusion = 282

# of reviewed records excluded based on:
• Lack of clinical or control group(s) = 53
• Wrong assessment tools used = 48
• Wrong outcomes = 28
• Wrong patient population = 32
• Insufficient information/data = 26
• Inappropriate study type = 23

# of records
identified by
snowballing
=4

# of records included in quantitative synthesis = 72

# of effects retrieved = 681

• 32 neuropsychology*
• 21 neuroimaging**
• 19 medication
* 3 TBI studies were coded
individually for the multiple
groups evaluated based on
TBI severity
** 5 studies featured both
neuroimaging and
neuropsychological data

Figure 16. Flow Chart of Study Screening and Selection
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